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C-JUN N-TERMINAL KINASE INHIBITORY NANOTHERAPEUTICS FOR 
REGENERATIVE ELASTIC MATRIX REPAIR IN ABDOMINAL AORTIC 
ANEURYSMS 
ANDREW T. CAMARDO 
ABSTRACT 
Abdominal aortic aneurysms (AAA) are localized expansions of the aorta wall that 
continue to grow until they reach a critical size and fatally rupture. This growth is driven 
by the chronic disruption, degradation, and subsequent loss of aortal wall elastic fibers by 
matrix metalloproteinases (MMPs) secreted by inflammatory cells recruited to the aorta 
wall following an injury stimulus, and the inherent inability of vascular smooth muscle 
cells (SMCs) to naturally repair or regenerate elastic fibers. This leads to a net loss of elastic 
matrix and the continuing weakening of the aortal wall until eventual rupture. Current 
treatments seek to reinforce the vessel wall with grafts or stents, but do not arrest or reverse 
AAA growth. Therefore, inhibiting the proteolytic degradation of the elastic matrix while 
also stimulating elastic matrix neoassembly is needed to stop AAA growth and regenerate 
the vessel wall. We have previously shown utility of doxycycline (DOX), an MMP 
inhibitor drug, to stimulate elastic matrix neoassembly and crosslinking at low µg/ml doses 
in addition to inhibiting MMPs. We currently show in aneurysmal SMC cultures, that 
effects of exogenous DOX in this dose range are linked to its upregulation of transforming 
growth factor beta (TGF-β1) via its inhibition of the regulatory protein c-Jun-N-terminal 
kinase isoform 2 (JNK 2). We have identified a DOX dose range that stimulates 
elastogenesis and crosslinking without adversely impacting cell viability. Using JNK 2 
inhibition as a metric for pro-regenerative matrix effects of DOX, we further demonstrate 
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that sustained, steady state release of DOX at the useful dose, from poly(ethylene glycol)-
poly(lactic glycolic acid) nanoparticles (NPs) provides pro-elastogenic and anti-proteolytic 
effects that could potentially be more pronounced than that of exogenous DOX. We 
attribute these outcomes to previously determined synergistic effects provided by cationic 
amphiphile groups functionalizing the polymer NP surface. Released DOX inhibited 
expression and phosphorylation of JNK to likely increase expression of TGF-β1, which is 
known to increase elastogenesis and lysyl oxidase-mediated crosslinking of elastic matrix.  
Our results suggest that JNK inhibition is a useful metric to assess pro-elastic matrix 
regenerative effects and point to the combinatorial regenerative benefits provided by DOX 
and cationic-functionalized NPs. 
 
  
vi 
 
TABLE OF CONTENTS 
 
ABSTRACT ...................................................................................................................... iv 
LIST OF TABLES ........................................................................................................... xi 
LIST OF FIGURES ........................................................................................................ xii 
INTRODUCTION............................................................................................................. 1 
1.1 Organization of thesis ........................................................................................ 4 
BACKGROUND ............................................................................................................... 5 
2.1 Vascular anatomy and physiology ......................................................................... 5 
2.1.1 Tunica adventitia ................................................................................................ 6 
2.1.2 Tunica media ...................................................................................................... 7 
2.1.3 Tunica intima ...................................................................................................... 9 
2.2 Extracellular matrix components ........................................................................ 10 
2.2.1 Collagen............................................................................................................ 10 
2.2.2 Glycosaminoglycans and proteoglycans .......................................................... 13 
2.3 Elastin ..................................................................................................................... 14 
2.3.1 Elastin structure ............................................................................................... 14 
2.3.2 Elastic fiber assembly and properties .............................................................. 15 
2.3.3 Role of elastin in healthy tissue ........................................................................ 18 
2.3.4 Elastin abnormalities ........................................................................................ 19 
vii 
 
2.4 Abdominal aortic aneurysm (AAA) .................................................................... 21 
2.4.1 Etiology and pathology of AAA ........................................................................ 21 
2.4.2 Diagnosis, incidence, and mortalities due to AAAs .......................................... 23 
2.5 Current treatments for AAA ................................................................................ 25 
2.5.1 Open surgery .................................................................................................... 26 
2.5.2 EVAR ................................................................................................................ 27 
2.5.3 Non-surgical management ................................................................................ 28 
2.6 Therapeutic strategies to restore vascular elastin .............................................. 29 
2.6.1 Elastin preservation .......................................................................................... 29 
2.6.2 Replacement of elastic matrix ........................................................................... 30 
2.7 Strategies for regenerative repair of elastic matrix ........................................... 33 
2.7.1 Scaffolds............................................................................................................ 34 
2.7.2 Stem cells for elastin regeneration ................................................................... 35 
2.7.3 Biological factors ............................................................................................. 36 
2.8 Doxycycline ............................................................................................................ 36 
2.8.1 Oral DOX therapy ............................................................................................ 37 
2.8.2 Biphasic dose effects of DOX ........................................................................... 37 
2.8.3 DOX delivery from nanoparticles (NPs) .......................................................... 38 
2.9 JNK ......................................................................................................................... 39 
MATERIALS AND METHODS ................................................................................... 41 
viii 
 
3.1 Isolation and culture of SMCs from elastase perfusion-induced rat AAAs .... 41 
3.2 Experimental design for cell culture studies ....................................................... 42 
3.3 Experimental design for DOX dosing cell culture studies ................................. 44 
3.4 Western blot for JNK, pJNK, MMP 2 and 9, TIMP-1, and LOX proteins ..... 46 
3.5 Gel zymography for MMP activity ...................................................................... 47 
3.6 ELISA for TGF-β1 expression ............................................................................. 48 
3.7 DNA assay .............................................................................................................. 48 
3.8 Fastin assay for elastin .......................................................................................... 48 
3.9 Desmosine assay..................................................................................................... 49 
3.10 Immunofluorescence (IF) labeling ..................................................................... 49 
3.11 Transmission Electron Microscopy (TEM) ...................................................... 50 
3.12 DOX-free NP formulation .................................................................................. 51 
3.13 DOX-loaded NP formulation ............................................................................. 52 
3.14 Measuring DOX encapsulation efficiency ......................................................... 53 
3.15 Size and surface charge of DOX-loaded PLGA NPs ........................................ 53 
3.16 DOX release from NPs ........................................................................................ 53 
3.17 Surface hydrophobicity of NPs .......................................................................... 54 
3.18 NP erosion profile ................................................................................................ 55 
3.19 NP effects on cell viability ................................................................................... 55 
ix 
 
3.20 Experimental design for cell culture studies to assess effects of NP treatment
 ....................................................................................................................................... 56 
3.21 Amplex red peroxide assay for LOX enzyme activity ..................................... 58 
3.22 Immunofluorescence (IF) detection of elastic matrix ...................................... 58 
3.23 Transmission electron microscopy (TEM) of deposited elastic matrix .......... 59 
3.24 Statistical Analysis............................................................................................... 60 
RESULTS ........................................................................................................................ 61 
4.1 Effects of DOX on expression of signaling proteins and MMPs/TIMP-1 ........ 61 
4.2 Effects of DOX dosing regimen on elastic matrix deposition and crosslinking67 
4.3 Effects of DOX dose on signaling proteins and MMPs/TIMP-1 ....................... 72 
4.4 Effects of DOX dosing on cell proliferation and on elastic matrix deposition 
and crosslinking ........................................................................................................... 79 
4.5 Effects of choice of surfactant on PEG-PLGA NP properties .......................... 85 
4.6 Formulation and characterization of DOX-loaded PEG-PLGA NPs .............. 87 
4.7 DOX release from PEG-PLGA NPs in vitro ....................................................... 88 
4.8 Erosion of PEG-PLGA NPs .................................................................................. 89 
4.9 Assessing cytotoxicity of DOX-loaded PEG-PLGA NPs ................................... 90 
4.10 Effects of DOX NPs on signaling protein and MMPs/TIMP-1 expression .... 91 
4.11 Effects of DOX NPs on cell proliferation, elastic matrix deposition and 
crosslinking .................................................................................................................. 98 
x 
 
DISCUSSION ................................................................................................................ 105 
CONCLUSIONS AND RECOMMENDATIONS ...................................................... 117 
REFERENCES .............................................................................................................. 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF TABLES 
Table 3.1a Design of culture experiments to assess effects of exogenous DOX (single 
dose) on JNK, MMP/TIMP, and TGF- expression in cytokine-injured EaRASMC layers 
(7 days) .………………………………………………………………………………….43 
Table 3.1b Design of experiment to assess effects of DOX dosing regimen (single or repeat 
additions of DOX at 5 µg/mL) on elastic matrix neoassembly and proteolytic activity in 
cytokine-injured EaRASMC cultures (21 days) ..………………………………………..44   
Table 3.2a Design of experiment to assess DOX dose–dependent effects on JNK, 
MMP/TIMP, and TGF-1 expression in cytokine-injured EaRASMC cultures (7 days) 
………..……………………………………………………………………………...…...45 
Table 3.2b Design of experiment to assess DOX dose-dependent effects on elastic matrix 
neoassembly and proteolytic activity in cytokine-injured EaRASMC cultures (21 days) 
…………………………………………………………………………………………....45     
Table 3.3a Design of experiment to assess effects of DOX NPs on cytokine-injured 
EaRASMC layers (7 days) ……………………………………………………………….56   
Table 3.3b Design of experiment to assess DOX NP effects on elastic matrix neoassembly 
and proteolytic activity in cytokine-injured EaRASMC cultures (21 days) …...…………58 
Table 4.1 Size and surface charge of PEG-PLGA NPs encapsulating DOX, formulated 
with DMAB as the emulsion stabilizer …………….…………………………………….87 
Table 5.1 Correlation coefficients of results ……………………………………………109  
xii 
 
LIST OF FIGURES 
 
Figure 2.1 Illustration of the arterial anatomy and the three vessel wall layers ……..……..6 
Figure 2.2 Schematic illustrating collagen assembly into higher order structures …….…11 
Figure 2.3 SEM images of various elastin ultrastructures ……………………………….15 
Figure 2.4 Schematic of steps involved in elastic fiber assembly ………………………..16 
Figure 2.5 Schematic of elastic fiber stretch and relaxation ……………………………..18 
Figure 2.6 Flow chart showing steps in etiology of AAAs ………………………………23 
Figure 2.7 Timeline of AAA growth/progression with treatment options ……………….24 
Figure 2.8 Representation of AAA and repair methods …………………………….........25 
Figure 2.9 General approach for tissue engineering of blood vessels ……………………33 
Figure 2.10 Schematic showing pro-elastin regenerative and anti-proteolytic effects of 
multifunctional DOX-NPs for AAA wall repair …………………………………………39 
Figure 3.1 Chemical structure of the cationic stabilizers used in the NP formulations …..52 
Figure 4.1 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of JNK …62 
Figure 4.2 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of pJNK .63 
Figure 4.3 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of MMP-2 
……………………………………………………………………………………………64 
xiii 
 
Figure 4.4 Effects of exogenous DOX at a trial dose of 5 g/ml on MMP-2 enzymatic 
activity …………………………………………………………………………………...65 
Figure 4.5 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of TIMP-1 
……………………………………………………………………………………………66 
Figure 4.6 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of TGF-1 
……………………………………………………………………………………………67 
Figure 4.7 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on cell 
proliferation ……………………………………………………………………………...68 
Figure 4.8 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on elastic 
matrix deposition ………………………………………………………………………...69 
Figure 4.9 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of LOX ..70 
Figure 4.10 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on 
desmosine crosslinking of elastic matrix ………………………………………………...71 
Figure 4.11 Immunofluorescence (IF) micrographs of the elastic matrix after exogenous 
DOX treatment at a trial dose of 5 g/ml …………………………………..……………..72 
Figure 4.12 Effects of exogenous DOX dose on expression of JNK …………………….73 
Figure 4.13 Effects of exogenous DOX dose on expression of pJNK …………………...74 
Figure 4.14 Effects of exogenous DOX dose on expression of MMP-2 ………………..76 
xiv 
 
Figure 4.15 Effects of exogenous DOX dose on MMP enzyme activity ………………...77 
Figure 4.16 Effects of exogenous DOX dose on expression of TIMP-1 …………………78 
Figure 4.17 Effects of exogenous DOX dose on expression of TGF-1 …………………79 
Figure 4.18 Effects of exogenous DOX dose on cell proliferation ………………………80 
Figure 4.19 Effects of exogenous DOX dose on elastic matrix deposition ………………81 
Figure 4.20 Effects of exogenous DOX dose on expression of LOX ……………………82 
Figure 4.21 Effects of exogenous DOX dose on desmosine crosslinking of elastic matrix 
……………………………………………………………………………………………83 
Figure 4.22 Immunofluorescence (IF) micrographs of elastic matrix after exogenous DOX 
dose treatment ……………………………………………..……….. …………………...84 
Figure 4.23 Transmission electron micrographs of elastic matrix after exogenous DOX 
dose treatment …………………………………………………...……………………….85 
Figure 4.24 Effect of choice of cationic amphiphile surfactants and surfactant 
concentrations on hydrophobicity, hydrodynamic sizes, and surface zeta potential of PEG-
PLGA methyl ether NP formulations …………………………………………………….86 
Figure 4.25 Transmission electron micrographs of 0% and 10% w/w DOX-loaded PEG-
PLGA-methyl ether NPs …………………………………………………………………88 
Figure 4.26 In vitro DOX release from PEG-PLGA methyl ether NPs loaded with 2, 5, 
and 10% w/w ratio of DOX to PEG-PLGA at a NP concentration of 0.5 mg/mL ………...89 
xv 
 
Figure 4.27 Plots showing time profile of in vitro DOX release from 10% w/w DOX-NPs 
at 0.2 mg/mL and 0.5 mg/mL concentrations …………………………………………….89 
Figure 4.28 Erosion profiles of 0% w/w DOX-NPs and 10% w/w DOX-NPs at 
concentrations of 0.2 and 0.5 mg of NPs/mL …………………………………………….90 
Figure 4.29 Schematic showing design of DOX-releasing PEG-PLGA methyl ether NPs 
……………………………………………………………………………………………91 
Figure 4.30 A LIVE/DEAD cytotoxicity assay of EaRASMCs exposed for 24 h to 0% and 
10% w/w DOX-loaded PEG-PLGA-methyl ether NPs …………………………………..91 
Figure 4.31 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on 
expression of JNK ……………………………………………………………………….92 
Figure 4.32 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on 
expression of pJNK ……………………………………………………………………...93 
Figure 4.33 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on expression of MMP-2 ……………………………………………………......95 
Figure 4.34 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on MMP-
2 enzymatic activity ……………………………………………………………………...96 
Figure 4.35 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on 
expression of TIMP-1 ……………………………………………………………………97 
Figure 4.36 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on 
expression of TGF-β1 ………………………………..………………………………..…98 
xvi 
 
Figure 4.37 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on cell 
proliferation ……………………………………………………………………………...99 
Figure 4.38 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on elastic 
matrix deposition ……………………………………………………………………….100 
Figure 4.39 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on LOX 
expression ………………………………………………………………………………101 
Figure 4.40 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs on LOX 
enzyme activity …………………………………………………………………………101 
Figure 4.41 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs on desmosine 
crosslinker ……………………………………………………………………………...102 
Figure 4.42 Immunofluorescence (IF) micrographs of elastic matrix after NP treatment 
…………………………………………………………………………………………..103 
Figure 4.43 Transmission electron micrographs of elastic matrix after NP treatment ….104 
Figure 6.1 DOX-NP mechanisms of matrix regenerative repair for restoring ECM 
homeostasis in the aneurysmal aortic wall ……………………………………………...118 
1 
 
 
 
 
 
CHAPTER I 
INTRODUCTION 
 
Abdominal aortic aneurysms (AAA) are asymptomatic, localized expansions of the 
abdominal aorta wall that grow slowly over several years to possible rupture. Chronic 
matrix metalloproteinase (MMP)-mediated disruption and loss of the elastic fibers within 
the extracellular matrix (ECM) of the aorta wall results in wall thinning and weakening 
and loss of elasticity. The risk of AAA rupture increases dramatically as the maximal 
diameter of the AAA segment exceeds a critical size of 5.5 cm1. Rupture of the abdominal 
aorta requires immediate surgery and is fatal in 90% of cases2. The disease mostly afflicts 
the elderly and is prevalent in 3.9% to 7.2% of men over the age of 50 and 1% to 1.3% of 
women3. Due to high procedural risk and post-operative complications, surgery (open or 
endovascular) is only performed on large diameter (> 5.5 cm) AAAs that are at a high risk 
of rupture. Elective surgery or endovascular aneurysm repair (EVAR) have been shown to 
have little benefit to preventing growth of smaller AAAs. Accordingly, small AAAs are 
only managed by passive surveillance using imaging techniques such as ultrasonography, 
computed tomography and MRI2,4. At this time, there are no active drug based treatments 
to arrest or reverse growth of small AAAs, which can prolong over 5-7 years.
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In healthy tissues, MMPs have a role in matrix remodeling and homeostasis, but 
MMP-2 and MMP-9 are overexpressed in the AAA wall by inflammatory cells and lead to 
a net loss of elastic matrix5,6. Adult aortic smooth muscle cells poorly synthesize elastin 
and are unable to produce sufficient amounts to repair or replace the disrupted/lost elastic 
matrix6,7. Due to this, restoring elastic matrix homeostasis- a necessary condition to achieve 
AAA growth arrest or regression to a healthy state, has been a critical and yet 
unsurmounted challenge. To enable this, an active stimulus to elastic fiber neoassembly 
must be provided, concurrent with inhibition of matrix breakdown5. Previous studies have 
shown doxycycline (DOX), a modified tetracycline, to non-specifically inhibit a spectrum 
of MMP types6,8,9. DOX inhibits MMPs by direct coordination with the catalytic site of the 
enzymes and also inhibits transcription of MMP mRNA9. At low, sub-clinical doses (< 10 
μg/mL), for the first time, we showed DOX to have pro-elastogenic effects in addition to 
continuing to inhibit MMPs. In doing so, the effects of DOX are broadly consistent with 
that of the drug, SP600125, an inhibitor of c-Jun-N-terminal Kinase (JNK), also known as 
mitogen activated protein kinase 9 (MAPK9), a regulatory protein. JNK inhibition with 
SP600125 has been linked to downstream effects of MMP inhibition, and slowed AAA 
growth when delivered in vivo10, though effects on the elastic matrix were not studied, and 
the drug is known to have off-target effects and minimally inhibit MMP-2, which is central 
to AAA development and growth. JNK has also been shown to antagonize transforming 
growth factor beta 1 (TGF-β1), which previous studies in our lab have shown to stimulate 
elastic matrix production by aneurysmal smooth muscle cells (AAA SMCs)6,9,11. 
In situ regenerative repair of the elastic matrix within the AAA wall demands 
modalities for localized, predictable, and sustained delivery of matrix regenerative/anti-
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proteolytic drugs, such as DOX, to assure dose-specific biological responses in target 
tissues, and to also avoid systemic MMP inhibition and body wide side effects of systemic 
DOX dosing. In a prior study, we developed cationic amphiphile-modified poly-lactic-co-
glycolic acid nanoparticles (PLGA-NPs) for this purpose, and demonstrated significant 
anti-MMP and pro-elastogenic/crosslinking effects on cultured aneurysmal SMCs that we 
attributed to both the DOX released in the desired low μg/mL range and the pendant 
amphiphiles on the NP surface 9,12. 
Based on these evidences, in this work, we sought to investigate in cell cultures if 
the anti-MMP and pro-elastogenic effects of DOX on cultured AAA SMCs at low doses is 
mediated by its inhibition of JNK, and if levels of JNK inhibition can be used as a metric 
to assess quantity and quality of induced elastic matrix regenerative repair. Additionally, 
we have also sought to investigate delivery of DOX from multifunctional NPs based on a 
diblock copolymer of PLGA and polyethlyene glycol (PEG), the latter intended to provide 
stealth properties within circulation and upon infiltration into the inflammatory cell-rich 
AAA wall in vivo. We have sought to investigate the effectiveness of DOX, released at 
doses optimized based on the metric of significant JNK inhibition, in both stimulating 
elastic matrix neoassembly and inhibiting proteolysis in aneurysmal SMC cultures, and 
also if these effects are synergistically improved by the cationic-amphiphile-surface 
functionalized PEG-PLGA nanocarriers.  
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1.1 Organization of thesis 
 
 Chapter II provides a background overview of the vascular anatomy and 
physiology, AAA etiology, current treatment options for AAAs and strategies for 
regenerative repair of elastic matrix, the role of doxycycline, and the role of JNK. Chapter 
III details the experimental design and methods adopted in these studies. Chapter IV 
presents the results from the experiments described in Chapter III. Chapter V interprets and 
discusses the results shown in Chapter IV. Chapter VI summarizes the work done in this 
thesis and suggests recommendations for future studies to bolster this work. 
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CHAPTER II 
BACKGROUND 
 
2.1 Vascular anatomy and physiology 
 Arteries in the cardiovascular system are responsible for transporting blood and 
nutrients throughout the body and are classified as elastic, muscular, or arterioles.  In order 
to do so, blood vessels, specifically the large elastic arteries, undergo high systemic 
pressure and must be able to expand and contract during cardiac systole and diastole to 
allow propagation of blood flow. This elastic recoil is a defining characteristic of arteries 
such as the aorta and pulmonary arteries, and helps them maintain a relatively constant 
systemic blood pressure13,14. Muscular arteries branch from elastic arteries and supply 
blood to specific organs, while arterioles lead to capillary beds. The physical properties 
and functions of arteries are a result of the structure and organization of the cells and 
extracellular matrix (ECM). Three concentric layers form the blood vessel wall and have 
distinct cellular and ECM compositions, and functions. Starting from the outermost layer, 
the order is tunica adventitia, tunic media, and tunica intima (Figure 2.1)13.   
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Figure 2.1 Illustration of the arterial anatomy and the three vessel wall layers, reprinted 
with permission from Patel et al 201615.  
 
2.1.1 Tunica adventitia  
 The tunica adventitia forms the outermost layer of the vessel wall and is mainly 
composed of fibroblasts and collagenous ECM that connect the vessel to the surrounding 
connective tissue. The tunica adventitia is innervated and facilitates cell signaling between 
the vessel and its surrounding tissue16. Vasa vasora, a network of small capillaries, supplies 
the tunica adventitia with blood and nutrients. Fibroblasts regulate the ECM content 
through production and degradation of proteoglycans, tenascin, laminin, and 
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fibronectin16,17. However, collagen (primarily collagen types I and III in aortae) and 
glycosaminoglycans (GAGs) are the main components of the ECM produced by fibroblasts 
within the tunica adventitia18. Fibroblasts synthesize massive amounts of pro-collagen 
molecules, but only a small percentage is released from the cell. Most of the pro-collagen 
is degraded intracellularly and can be released when needed to respond and adapt to 
changes in structural need19. The high collagen content strengthens and structurally 
supports the vessel and prevents over expansion and rupture from luminal blood pressure14. 
Collagen will be reviewed in greater detail in later sections. Fibroblasts also produce matrix 
metalloproteinases (MMPs) that degrade ECM proteins and conversely produce tissue 
inhibitors of metalloproteinase (TIMP) to further regulate ECM composition. The balance 
of MMPs and TIMPs is crucial to maintaining ECM homeostasis, so fibroblast dysfunction 
can lead to a disease state 13,20–22. Furthermore, fibroblasts can have an active or inactive 
phenotype. When activated, fibroblasts are involved in proliferation, differentiation and 
upregulation of ECM proteins. During inflammation and vessel injury, fibroblasts activate 
and differentiate into myofibroblasts that readily generate a new collagen-rich matrix that 
can alter tissue structure. Although the components of the tunica adventitia are consistent 
throughout arteries, the ratios of the components and orientation of the ECM fibers can 
vary depending on the loading requirements of the vessel17,23. 
2.1.2 Tunica media  
 The tunica media is the middle and thickest layer of the blood vessel wall and it is 
separated from the surrounding layers by the internal and external elastic lamellae. It is 
primarily composed of vascular smooth muscle cells (SMCs), elastin, and collagen types I 
and III, with elastin accounting for up to 50% of the vessel’s dry weight13. Fenestrated 
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elastic lamellae surround these circumferentially aligned SMCs, elastic fibers, and collagen 
fibers to form a structural unit referred to as a lamellar unit24.  
 SMCs are predominantly located in the tunica media and function to regulate blood 
vessel diameter, blood pressure, and blood flow distribution. In the mature contractile 
phenotype, SMCs are spindle shaped and circumferentially aligned and layered. SMCs 
have a basal tone in vascular homeostasis, meaning they are partially contracted. This 
positioning allows for relaxation or contraction in response to the changing local 
environment25–27. Contraction can be stimulated by electrical, pharmacological, or 
mechanical means. Cell proliferation and synthetic activity are very limited in mature cells 
with the contractile phenotype. SMCs also display a proliferative or synthetic phenotype 
capable of producing large amounts of ECM such as collagen, elastin, proteoglycans, 
cadherins, and integrins. This phenotype is mainly displayed in late embryogenesis and 
post-natal development, but mature cells are capable of alternating between 
phenotypes25,28. Upon vessel injury and exposure to plasma constituents and lipids, mature 
contractile SMCs will transition into the synthetic phenotype to repair the damaged 
vessel29. Cytokines and growth factors such as PDGF, TGF-β1, and fibronectin facilitate 
the de-differentiation into the synthetic phenotype26. The structure and content of ECM 
also affects phenotype. The fibrillar form of collagen Type I activates the contractile 
phenotype, while collagen Type I monomers promote the synthetic phenotype30. Balance 
between the different phenotypes is an important aspect of blood vessel homeostasis and 
its disruption can lead to disease states. 
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2.1.3 Tunica intima 
 The tunica intima is the innermost layer of the blood vessel that lines the luminal 
surface and is composed of a monolayer of vascular endothelial cells (ECs) anchored to a 
basement membrane, a thin sheet of subendothelial connective tissue, and the internal 
elastic lamina which separates the tunica intima from the tunica media13,14. The basement 
membrane is composed of collagen, laminin, and proteoglycans and functions to provide a 
scaffold for EC attachment, regulate cell migration, act as a reservoir for growth factors, 
and facilitate cell signaling pathways. The ultimate function of the tunica intima is to act 
as a semi-permeable barrier between blood and the surrounding tissue31,32. 
 ECs have a simple squamous morphology and are arranged in a cobble stone pattern 
or are elongated when exposed to shear flow. They exhibit a polar surface, i.e. with basal 
and apical regions. In straight arterial segments, such as the abdominal aorta, ECs are 
aligned in the direction of flow and perpendicular to the direction of cyclical stretching, 
which aids in resistance to shear stress from blood flow32–34.  Tight junctions, anchoring 
junctions, and gap junctions connect ECs to each other and to the basement membrane and 
allow for cell to cell communication35. In addition to forming a permeable interface 
between circulating blood and the underlying tissue, ECs actively regulate vascular 
homeostasis through signaling pathways. To regulate blood pressure, ECs release 
vasodilators (e.g. nitric oxide) or vasoconstrictors (e.g. endothelin) to induce the relaxation 
and contraction of SMCs, respectively. ECs also have a role in regulating thrombosis and 
coagulation36,37. The glycocalyx, a negatively charged hydrated mesh of proteoglycans, 
GAGs, and glycoproteins bound to ECs, prevents thrombogenic proteins from adhering to 
the vessel surface. Additionally, ECs secrete anti-thrombogens and anti-coagulants, such 
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as prostacyclin and thrombomodulin, to inhibit platelet recruitment, activation, 
aggregation, and adhesion to limit thrombus formation38. Upon minor injury to the 
endothelium, new ECs migrate and proliferate to replace the damaged cells. More severe 
injuries require assistance from SMCs and fibroblasts while ECs regulate the remodeling 
of the vessel wall. In both healthy and disease states, ECs have an instrumental role in 
vascular homeostasis and maintaining the integrity of the blood vessel wall13,33. 
2.2 Extracellular matrix components 
 The vascular ECM is responsible for maintaining the structural integrity, 
biomechanics, and homeostasis of the vascular wall and aids in the regulation of the 
adhesion, migration, phenotype, and proliferation of the vascular cells during development 
and injury. The vascular ECM is constantly changing and remodeling in both healthy and 
injured or disease states to respond to internal and external stimuli. It is composed of a 
complex mixture of signaling and structural macromolecules, primarily collagen, GAGs, 
and elastin39,40. 
2.2.1 Collagen 
 Collagen is the most prevalent structural protein in the ECM and provides tensile 
strength and load bearing support to the vessel wall. Collagen is imperative to maintaining 
structural integrity and preventing vessel rupture19. Both SMCs and fibroblasts produce 
and secrete pro-collagen as a precursor molecule. Intracellular pro-collagen consists of 
three polypeptide α chains assembled into a triple stranded right-handed helix domain with 
propeptides on both ends. The amino acid chain typically consists of a series of glycine, 
proline and hydroxyproline41. The propeptides are cleaved upon secretion from the cell, 
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resulting in collagen molecules that undergo further self-assembly. The α chain helixes 
form a larger, left-handed helix with three amino acids per turn and a glycine as the third 
amino acid. Glycine, the smallest amino acid, faces the interior of the helix in the 
configuration which allows the chains to pack tightly and imparts strength on the 
assembly42. Collagen molecules can be assembled into supramolecular structures such as 
fibrils, microfibrils, filaments, and network like structures and then further into higher 
order structures including fibers and lamellae (Figure 2.2)13,41.  
 
Figure 2.2 Schematic illustrating collagen assembly into higher order structures. Adapted 
from Riso et al 201643. 
 
 As previously mentioned, the strength and durability of collagen fibers is crucial to 
its function as a load bearing structural support system for the vessel wall. The structural 
integrity of collagen molecules and higher order assemblies cannot be compromised. 
Hydrogen bonds between α chains stabilize the helical configuration and lysine helps form 
crosslinks between α chains and between collagen molecules42. High proline and 
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hydroxyproline content also contributes to triple helix stability. To protect against 
enzymatic proteolytic attack, the peptide bonds between amino acids in the polypeptide 
chains are located within the triple helix, effectively shielding them from most proteinases. 
However, collagenases are still able to degrade collagen molecules, but this allows for 
normal and regulated turnover of collagen during growth and remodeling44.  
 Collagen is actually a large family of molecules with the general structure and 
composition described above. The difference in family members results from the 
combination of differing α chains. This creates different sizes and locations of the helical 
domains, which affects the supramolecular structures and influences physiochemical 
properties41. Collagen molecules are classified as types based on their supramolecular 
assemblies and functions. Collagen type I, III, and V form fibrils and are prevalent in the 
arterial wall. These types will assemble to form mature cylindrical fibrils (10-500 nm in 
diameter) that will further assemble into fibers (0.5-3 μm in diameter) and fiber bundles 
that structurally support the vessel wall41. Collagen types I and III also provide passive 
mechanical resistance to circumferential loading in addition to axial loading. Improper 
production or assembly of these molecules is detrimental to the strength and vitality of the 
blood vessel wall41. Collagen type IV forms a basement membrane network in the basal 
laminae. These thin, flexible sheets provide some structural support, but also 
compartmentalize tissues and act as a reservoir for enzymes and cytokines19. Collagen type 
VIII also forms a short chain non-fibrillar network that aids in maintaining the mechanical 
stability of the vascular wall and in vascular repair and atherogenesis19. Collagen types XV, 
XVIII, and XIX are classified as fibril-associated collagens and also form the structure of 
the basement membrane. The variability in structure and shape of molecules in the collagen 
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family allows for versatility in its function and use in the blood vessel wall. In addition to 
its structural properties, collagen molecules can have anti-thrombogenic properties and can 
influence SMC migration, proliferation, and anchoring14,45,46. 
2.2.2 Glycosaminoglycans and proteoglycans 
 Glycosaminoglycans (GAGs) and proteoglycans (PGs) are components of the 
vascular ECM ground substance and covalently bond to each other to form a large bottle 
brush like aggregate with the PG acting as the protein core from which multiple GAGS 
branch out14. GAGs are linear polysaccharide chains composed of disaccharide repeating 
regions, which are typically composed of uronic acid (D-glucuronic acid or L-iduronic 
acid) and an amino sugar (N-acetylgalactosamine or N-acetylglucosamine). GAGs occupy 
a large volume and are strongly hydrophilic and negatively charged due to the carboxyl 
groups on most sugars within the chain. Osmotically active cations such as sodium ions 
are attracted to the negative charge and water is subsequently drawn into the matrix to form 
a gel-like structure47. This is an important feature of GAGs and allows the matrix to swell, 
and with the assistance of intertwined collagen fibers, resist compressive forces. GAGs and 
PGs are also known to regulate cell adhesion, proliferation, and migration within the 
ECM48. 
 GAGs and PGs are produced by SMCs and fibroblasts in the blood vessel wall, but 
most cell types are capable of this production. Vascular tissue GAGs are typically classified 
based on sulfation (chondroitin sulfate, dermatan sulfate, heparin sulfate), or lack thereof 
(hyaluronic acid). PGs are also classified based on distribution, function, and the specific 
GAGs bound to it. Hyaluronic acid (HA) has an important role in vasculogenesis in 
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developing tissue and is abundant in mature tissues during wound healing and 
inflammation49.  
2.3 Elastin 
 Elastin is another abundant structural protein in the vascular ECM and forms elastic 
fibers that allow for elastic deformation and resilience within tissues and plays an important 
role in the unique biomechanical properties of blood vessels. The elastic fibers are 
primarily in the tunica media and dynamically interact with SMCs to maintain vascular 
homeostasis. While elastin is a major component of arteries, it is also found in a variety of 
other connective tissues such as the skin, lungs, bladder, elastic cartilage, and elastic 
ligaments50.  
2.3.1 Elastin structure 
 Elastin is a hydrophobic protein synthesized as tropoelastin monomers (72 kDa) by 
SMCs and is abundant in proline, valine, glycine, leucine, isoleucine, and alanine residues. 
Tropoelastin consists of hydrophobic domains containing VGVAPG amino acid sequences 
that alternate with a crosslinking domain rich in lysine and alanine51. The crosslinking 
domains form α helices and the hydrophobic domains form β sheets, and the secondary 
structure of tropoelastin is characterized by these alternating α helices and β sheets52. The 
enzyme lysyl oxidase (LOX) forms desmosine crosslinks between α helices via a copper-
dependent oxidative deamination of the lysine side chains and subsequent condensation to 
stabilize the structure18. Both α helices and β sheets are energetically favorable 
conformations and their combination in elastin molecules creates a random coil structure 
exhibiting high entropy53.  
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Crosslinked elastin molecules can form a variety of ultrastructures with the ability 
to reversibly elongate and stretch due to these random coils. Elastin is typically 
ultrastructurally organized as individual or networked fibers with varying degrees of 
density. They can also form woven matrix structures such as continuous sheets, fenestrated 
sheets, or fiber meshes54 (Figure 2.3). These structures provide tissues with elastic 
properties and allow stretching and recoil. 
 
Figure 2.3 SEM images of various elastin ultrastructures. Adapted from Scott et al 199655. 
 
2.3.2 Elastic fiber assembly and properties  
 In vascular tissue, the elastic matrix is composed of elastic fibers that mesh to form 
circumferentially oriented and concentric elastic lamellae. Elastic matrix assembly 
primarily occurs during early development and wanes beyond adolescence6. However, the 
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half-life of elastin is roughly 74 years due to its high hydrophobicity and crosslinking, so 
the elastin produced during this period is sufficiently stable over an individual’s lifetime. 
The multi-step process of elastic matrix assembly is illustrated in Figure 2.4. 
 
Figure 2.4 Schematic of steps involved in elastic fiber assembly. 
Elastin is initially secreted into the extracellular space as the precursor molecule 
tropoelastin, which is encoded by a single copy gene ELN in SMCs and fibroblasts. The 
hydrophobic domains (composed of hydrophobic amino acids) of tropoelastin engage with 
and bind to elastin binding protein (EBP)54. EBP is a membrane protein that protects 
tropoelastin from degradation in the extracellular environment. Tropoelastin then 
disassociates from the EBP and coalesces on the microfibrillar glycoprotein scaffold that 
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are orientated as linear arrays. LOX crosslinks the lysine side chains of the crosslinking 
domains to form desmosine and isodesmosine linkages between elastin molecules56. This 
process is repeated as the fiber extends. The microfibrillar scaffold is essential in elastic 
fiber assembly because it (1) provides spatial coordination and alignment for the 
assembling tropoelastin to crosslink and extend, (2) maintains fiber integrity as it grows, 
and (3) facilitates biomechanical transduction of contacting cells by the elastic fibers54.  
Mature elastic fibers have a 300 nm – 2 µm cross sectional diameter and have a 
central core of crosslinked elastin molecules surrounded by microfibrils6. The desmosine 
crosslinks between molecules within the fibers impart unique mechanical properties. Upon 
stretching, the randomly coiled elastin molecules straighten to elongate the fiber, but the 
crosslinks limit the extent of elongation (Figure 2.5). This allows the fibers to stretch, but 
also recoil and assume their relaxed state as a unit. Elastic fibers exhibit high elasticity, 
deformability, passive recoil, and low hysteresis18. The mechanical properties of individual 
elastic fibers are retained as they form higher order structures and provide the same 
properties to these structures. 
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Figure 2.5 Schematic of elastic fiber stretch and relaxation. The crosslinks (red) prevent 
overextension of elastin molecules (green). Adapted from Alberts et al 200257. 
 
2.3.3 Role of elastin in healthy tissue 
Due to its unique mechanical properties, the elastic matrix plays an important role 
as a primary load bearing structural matrix component in large arteries at physiological 
pressures13. Elastic lamellae in the arterial wall provide the needed elasticity to absorb and 
withstand the hemodynamic stresses of blood pressure during cardiac systole and transmit 
this stored energy to propel blood forward during diastole, without permanent deformation 
or damage. The vascular elastic matrix, comprised of axial and circumferential fibers in the 
vessel wall, also helps distribute forces during contraction and relaxation of the vessel. 
Similarly, this allows blood vessels to handle high pressure and stress without bursting45. 
In addition to its role in the mechanics in healthy tissue, elastin is key to maintaining 
biochemical homeostasis in the vessel wall. The elastic matrix serves as a reservoir for 
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growth factors and cytokines, therefore influencing the survival, proliferation, 
differentiation, and migration of vascular cells51,53. Vascular cells, especially SMCs, are 
embedded in the elastin-rich ECM which reduces their ability to migrate, and tropoelastin 
promotes cell adhesion54. Mature elastin also inhibits cell proliferation and induces actin 
stress fiber orientation. However, elastin peptides resulting from degradation of the elastic 
matrix have different effects on the vascular cells and tissue50. 
2.3.4 Elastin abnormalities  
 Genetic mutations can result in elastin (or elastic matrix) abnormalities. Mutations 
in elastin (ELN), fibulin (FBN), or fibrillin (FBLN) genes can impair elastin synthesis, 
crosslinking, or fiber assembly resulting in defective elastic matrix and the ECM as a 
whole53. Mutations in the components at any point of elastic fiber assembly can result in a 
defective elastic fiber. Typically, as a result of these mutations, elastic fibers undergo early 
fragmentation and degradation, which negatively impacts the functioning of the artery46. 
The problems with the elastic matrix can lead to vascular diseases such as aneurysms or 
stenosis and can be fatal.  In other cases, the elastin in other tissues, such as the skin and 
skeletal tissue, are affected. Common genetic disorders include Marfan’s syndrome, 
William-Beuren syndrome, and autosomal recessive cutis laxa14. 
 In addition to genetic disorders, abnormalities in the elastic matrix can be acquired 
from illness, injury, or lifestyle choices. Injury to vascular tissue causes inflammation and 
leads to an overexpression of MMPs and other proteases that degrade and break down the 
elastic matrix22,46. This degradation creates elastin peptides that further exacerbate the 
pathologic conditions from inflammation53. Elastin peptides activate MMPs and induce a 
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diseased, proliferative phenotype in SMCs with enhanced cytokine production53. 
Alternately, elastin peptides stimulate SMC apoptosis, which leads to more elastic matrix 
breakdown46. They also calcify the tissue by influencing an increased uptake in calcium 
ions which leads to hardening of the tissue and increased inflammatory cell recruitment 
(typically neutrophils and macrophages)58. This all acts to form a feedback loop that causes 
further breakdown of the matrix and the subsequent generation of more elastin peptides.  
 Other acquired cardiovascular pathologies, such as atherosclerosis and 
arteriosclerosis, involve exaggerated vessel wall remodeling and synthesis, resulting in the 
thickening, stiffening, and occlusion of the vessel wall46. Generally, an injury or other 
stimulus to the vessel wall causes inflammation that eventually leads to improper vascular 
cell proliferation and migration and elastic matrix disruption. Initially, inflammation 
recruits peripheral blood monocytes (that polarize to macrophages) and T-lymphocytes that 
adhere to the endothelium and activate, resulting in a cascading production of cytokines 
and growth factors such as PDGF, epidermal growth factor, fibroblast growth factor, and 
TGF-158,59. Upon this signaling, SMCs transform into a synthetic phenotype to proliferate 
and migrate into the inflamed region where they synthesize excess ECM components. The 
combined effects of rapid cell proliferation and ECM production results in the formation 
of a plaque and eventual atherosclerotic lesion in the tunica intima and lumen composed of 
SMCs and lymphocytes in a fibrous cap, and macrophages, lipids, and lipoproteins in the 
core46. The fibrous plaque or lesion results in the thickening and stiffening of the vessel 
wall and can eventually lead to occlusion or separately, thrombosis and embolism 
formation20.  
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2.4 Abdominal aortic aneurysm (AAA) 
 AAAs are a vascular disorder characterized by slow growing, local expansions of 
the abdominal aorta wall due to the chronic, irreversible proteolytic breakdown of the 
elastic matrix and the inability of adult vascular cells (SMCs, fibroblasts) to regenerate or 
repair the elastic matrix, resulting in a progressive weakening of the wall until eventual, 
fatal rupture. AAAs occur in the descending aorta below the diaphragm and between the 
aortic bifurcations. They are clinically defined as representing 50% or greater increase in 
diameter compared to the healthy size, but a diameter of 3 cm is commonly regarded as the 
threshold2. Risk factors for AAA formation and development include smoking, 
atherosclerosis, chronic hypertension, and infection or trauma in the vessel wall1.  
2.4.1 Etiology and pathology of AAA 
Multiple factors, such as trauma, hypertension, or inflammation, can provide initial 
stimulus to trigger AAA formation. Figure 2.6 shows the progression of AAA formation. 
After the initial injury or stimulus to the aortal wall, inflammatory cells such as 
macrophages and lymphocytes are recruited and infiltrate the injured tissue site2. These 
cells, along with ECs, SMCs, and fibroblasts, overexpress cytokines that initiate the release 
of MMPs, primarily MMP-2 and MMP-9, which start to degrade elastin and collagen in 
the elastic matrix39.  Due to the poor elastogenic capabilities of mature and diseased SMCs, 
no new elastin is synthesized and a net loss of elastin and elastic fibers occurs during this 
degradation26. The previously described elastin peptides are also generated and cause more 
elastic matrix degradation and breakdown. Elastin peptide induced apoptosis in SMCs also 
acts to reduce the number of ECM producing cells in the aortal wall, further reducing elastic 
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matrix content60. The thinning of the vessel wall from the loss of elastic fibers effects the 
mechanical properties of the vessel wall, and the vascular cells perceive an increase in 
stresses and forces from blood flow7. Since SMCs still readily produce and deposit collagen 
in this state, they respond to the new amplified mechanical stimulus by increasing 
production and deposition of collagen into the ECM in an attempt to strengthen the wall 
against the increased force60. The collagen increase temporarily stabilizes the vessel wall 
and accounts for the slow growth of AAAs over 5-7 years61. However, the mechanics of 
the vessel wall are altered and the vessel is stiffer and suffers from a loss of elastic recoil 
and elasticity. The chronic overexpression of MMP stimulating cytokines creates a 
continued state of proteolytic degradation of the elastic matric in which the vessel wall 
continually thins and weakens and the diameter of the aneurysm grows from 2.5 cm to over 
5 cm over the course of 5-7 years. At this point, fatal rupture occurs when the stress on the 
vessel wall exceeds the wall strength2. 
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Figure 2.6 Flow chart showing steps in etiology of AAAs. 
2.4.2 Diagnosis, incidence, and mortalities due to AAAs 
 AAAs are typically asymptomatic, which makes their detection and diagnosis 
difficult. Non-invasive ultrasonography, CT, or MRI is used to detect and then monitor 
AAA formation and growth. Pro-active, image-based screening of high risk individuals 
(e.g. elderly male smokers) frequently detects AAAs while they are still small (< 5.5 cm in 
diameter) and growing62. Once diagnosed, AAAs are continuously monitored until they 
surpass a diameter of 5.5 cm and are deemed a high risk for rupture. At this critical size, 
surgical intervention is required because the risk of rupture outweighs the risks associated 
with surgery, but before this point surgery is considered a greater risk, so patients will 
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undergo repeated ultrasonography every 3 to 12 months to monitor AAA growth63. AAAs 
typically grow approximately 1 cm per year. As mentioned before, high risk populations 
include elderly male smokers, but also those with a family history of AAAs, and frequently 
patients with other cardiovascular conditions such as atherosclerosis, hypertension, and 
hypercholesterolemia, and the obese3. Interestingly, diabetics, Hispanics, and African 
Americans have a reduced risk of AAA formation. AAAs afflicted nearly 9% of elderly 
men and 3% of elderly women and AAA rupture is the 13th leading cause of death in the 
United States63. Worldwide, over 20 million people die from AAAs which is a 12% 
increase in the last 20 years3. 
 
Figure 2.7 Timeline of AAA growth/progression with treatment options. 
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2.5 Current treatments for AAA 
 As previously described, there are currently no treatments for small diameter AAAs 
beyond passive, image-based monitoring until the risk of rupture becomes significant 
(Figure 2.7). Once the aneurysm diameter reaches a critical size over 5.5 cm, surgical 
intervention becomes an option and is commonly performed using open surgery or 
endovascular aneurysmal repair (EVAR) (Figure 2.8)64. Both of these options aim to 
prevent vessel wall rupture, but they have limitations. They only address the result of 
AAAs- not the root cause of AAA formation/growth. The immediate danger of vessel 
rupture is mitigated, but nothing is done to prevent the continued growth of the aneurysm, 
which has been documented after the completion of both of these techniques. This 
highlights the need to develop non-surgical therapies that both arrest and regress small 
diameter aneurysm growth before they reach the critical size65. 
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Figure 2.8 Representation of AAA. A: Representation of open repair surgery and 
placement of graft. B: Representation of EVAR and stent location. Reproduced with 
permission from Solomon and Kent 2014 2, Copyright Massachusetts Medical Society. 
 
2.5.1 Open surgery 
 In some cases, open surgery to replace the aneurysmal portion of the aorta may be 
warranted. In open surgery, an incision is made along the center of the abdomen to expose 
the aorta. Blood flow is then occluded by clamping the aorta at sites above and below the 
aneurysm. The aneurysmal portion of the aorta is partially or completely removed and 
replaced with a graft66. Grafts used in aortal replacement can be autologous, allogenic, 
xenogeneic, or synthetic. The choice of graft used depends on availability and ability to 
replicate the mechanical and biochemical properties of the native tissue. Autologous grafts 
are typically avoided due to incompatible mechanical properties, size, and availability, 
while allogenic and xenogeneic grafts are avoided due to graft rejection and elicited 
immune responses67. Mesh, synthetic grafts made with Teflon, Dacron, and polyurethane 
have had successful implementation as grafts. 
Open repair surgery is highly invasive and there are many risk factors, therefore 
this procedure is not recommended for elderly or weaker patients63. Complications (beyond 
the normal surgical risks) arising from graft application with open repair surgery include 
bleeding, small bowel obstruction, hernia, and ischemia66. However, once completed, it 
requires less monitoring than EVAR and is considered as a “for life” procedure68. 
Additionally, open repair patients have a 3-4 times smaller risk of graft related 
complications or re-intervention compared to EVAR patients and only 9% of patients who 
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underwent open repair surgery needed re-intervention62. However, this procedure does not 
address the physiological conditions that enabled AAA formation, so the patient is still 
susceptible to new or continued AAA growth.  
2.5.2 EVAR 
 EVAR is a minimally-invasive surgical procedure that inserts an expandable 
polymer stent into the lumen of the abdominal aorta at the site of the aneurysm65,69. The 
stent acts to structurally support the weakened vessel wall and reduce the forces from blood 
flow and pressure on the wall. The rationale is that by excluding the aneurysm from the 
hemodynamic forces, the vessel walls will be not be strained further, preventing additional 
weakening and rupture67. The use of a catheter for stent application makes this procedure 
minimally-invasive. A stent loaded catheter is inserted into the femoral artery of the patient 
and guided to the aneurysm site, avoiding the need for open surgery. The stent is in a 
compressed configuration until it reaches the aneurysm site where it will be expanded to 
the necessary size65. There are limitations and disadvantages to this procedure beyond the 
typical surgical risks such as infection. The stent is not a long term treatment due to 
durability issues and the potential for stent migration away from the aneurysm site. 
Additionally, the stent can cause endoleaks (i.e. blood flow around the graft), occlusion or 
thrombosis69. The stent must be monitored after the operation and throughout its lifetime 
in the body and the re-intervention rate for patients with EVAR is 41%. As previously 
mentioned, surgery does not actually address the factors that cause AAA growth, and over 
70% of administered EVARs have failed in stopping aneurysm growth65.  
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2.5.3 Non-surgical management 
 There are also non-surgical therapies that seek to manage the growth of AAAs using 
pharmaceuticals including β blockers, angiotensin-converting enzyme (ACE) inhibitors, 
antiplatelet agents, anti-inflammatories, and statins. To be clear, these are not FDA-
approved or proven to successfully treat AAAs, but they are in the development 
pipeline1,65. The goal of these pharmaceutical treatments is to inhibit proteinases and reduce 
risk factors to slow AAA growth. β blockers, such as propranolol, have been used in trials 
for AAA treatment. β blockers lower blood pressure, which seeks to reduce the 
hemodynamic pressures on the aneurysmal wall so that the stress on the wall does not 
exceed the wall strength64. Unfortunately, propranolol treatments have not had much 
success in slowing AAA growth and many patients dropped out of the study due to adverse 
side effects65. Other drugs, such as Telmisartan, Ticagrelor, and valsartan, target 
inflammation and angiotensin in an attempt to slow AAA growth. However, they are not 
effective65. The MMP inhibitor DOX has also been studied as an AAA treatment and will 
be discussed in later sections. Although unlikely to arrest or regress AAA growth, changes 
in diet and lifestyle choices (e.g. smoking cessation) are recommended as to not further 
exacerbate the growth1. Additionally, these non-surgical AAA treatments have limitations 
similar to the surgical treatments. While they may reduce the proteolytic activity in the 
aneurysmal tissue, they do not stimulate the production and assembly of new elastic matrix. 
The arterial wall is not strengthened and regenerated, so the risk of rupture is still present. 
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2.6 Therapeutic strategies to restore vascular elastin 
 Loss of elastin and the elastic matrix is a central driving force in the formation and 
growth of AAAs. Therapeutic strategies can be utilized to prevent this degradation and 
restore vascular elastin homeostasis to combat AAA growth. Due to the inherently poor 
elastogenic capabilities of mature SMCs, preserving the existing elastin is a top priority. 
Different approaches and therapeutic targets have been used in this endeavor. 
Alternatively, there are strategies that aim to replace the elastic matrix entirely with 
synthetic elastomer grafts. Both of these strategies will be explored below. 
2.6.1 Elastin preservation  
 Elastin preservation strategies seek to maintain existing elastin within the elastic 
matrix by inhibiting proteolytic enzyme production or activity. Inhibition of MMPs and 
other general proteases are the main targets for this strategy due to their overexpression in 
aneurysmal tissue70. There are currently no FDA-approved drugs for AAA treatment, but 
there are several protease inhibitors in development including statins, tetracyclines, and 
ACE inhibitors1. These act to preserve the intact elastic matrix by slowing or preventing 
proteolytic degradation, but do not lead to the generation of new elastin. 
 Chronic overexpression of MMPs, specifically MMP-2 and MMP-9, are the main 
drivers of the proteolytic breakdown of the elastic matrix and are therefore potential 
therapeutic targets for elastin perseveration6. DOX is a well-known tetracycline based 
MMP inhibitor and has been shown to tentatively reduce AAA formation and growth in 
both rat AAA models and in human clinical trials8,71. Native TIMPs are normally 
responsible for MMP regulation, but there is an imbalance in the TIMP-MMP ratio in 
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aneurysmal tissues so exogenous TIMP delivery has been investigated as a means to arrest 
AAA growth. However, unless a localized and controlled delivery method is developed, 
systemic TIMP treatment could have adverse side effects in matrix homeostasis and 
turnover in healthy tissues6. α-1-antitrypsin, a prominent serine proteinase inhibitor, binds 
irreversibly to elastases and a deficiency can lead to chronic excessive proteolysis and 
elastin degradation. Therapies involving the delivery of α-1-antitrypsin have shown some 
ability to preserve the elastic matrix by inhibiting elastolysis6. Alternatively, the synthesis 
and assembly of MMPs can be prevented through the inhibition or deactivation of MMP 
related transcription factors and microRNAs6,62. Transcription factors and microRNAs 
regulate protein synthesis by regulating RNA formation, and is thus a target for therapy. 
Preserving the elastin remaining in the matrix may slow the growth of AAAs, but without 
a stimulus for new elastin synthesis, vessel wall regeneration to a healthy state cannot be 
achieved. The net loss of elastin must be compensated with new elastin. 
2.6.2 Replacement of elastic matrix  
 In some cases the elastic matrix is severely degraded and damaged beyond a point 
that they can be salvaged with elastin preservation therapies or by proteienase inhibition. 
If the structural integrity and stability of the vessel is compromised, the elastic matrix can 
be replaced or reinforced with a graft or other matrix substitute72. By removing or 
reinforcing the aneurysmal tissue, the hope is that the vessel regains its normal function 
and mitigates the threat of rupture. Natural and synthetic grafts or matrices have been 
developed, but they must meet certain requirements to be a suitable blood vessel substitute. 
They must have structural and mechanical properties consistent with the native tissue in 
order to avoid stress concentrations or improper loading. Additionally, substitutes should 
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be compliant, non-immunogenic, non-toxic, and non-thromobogenic. Replacement grafts 
can be autologous, allogenic or xenogeneic, or synthetic6,73. 
 As previously discussed, autologous grafts are harvested from a patient and utilized 
to replace the aneurysmal portion of the artery. Autologous grafts are advantageous 
because they elicit no immune response because they are the patient’s own tissue. 
However, autologous grafts are rarely used to replace the elastic matrix in the aorta due to 
incompatible mechanical properties and size and lack of availability61,67. 
 Allogenic tissue from donors or cadavers are another viable source of grafts that 
can potentially exhibit the desired mechanical properties and size to successfully replicate 
the native vascular tissue. There is a risk of a host immune response, so the patient must 
undergo life-long immunosuppressive drug treatment64. The elderly population is the major 
demographic for graft replacement and immunosuppressive therapy is extremely taxing, so 
allografts are typically avoided due to this major risk. However, there are new techniques 
that seek to utilize allogenic tissue and have lower immunogenicity. The donor tissues are 
decellularized with a detergent, leaving behind the ECM scaffold. The patient’s own cells 
are then used to repopulate the scaffold to create a viable blood vessel. The scaffold can be 
implanted without cells so that the native nearby cells migrate and repopulate, or cells can 
be harvested to be seeded and cultured in vitro before implantation. Similar to allografts, 
xenografts can be used with this technique but they are not ideal. There are risks involved 
with xenografts and they are prone to immune rejection, genetic mutations and disease 
transmission, so they are mostly avoided67. 
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 Synthetic polymer grafts are the most commonly used to treat AAAs because they 
avoid the immunogenic and availability issues seen in the previous options. They can be 
customized to ensure proper size and properties. Dacron (polyethylene terephthalate, PET), 
polyurethanes (PU), and Teflon (expanded polytetrafluoroethylene, ePTFE) are common 
materials used in grafts and they have differing properties for differing needs72. Differences 
in tensile strength between materials and native tissue can cause compliance issues.  For 
instance, Dacron has a tensile strength of 170-180 MPa, which is much larger than the aorta 
(800-1000 kPa)72. However, this strength contributes to Dacron’s ability to resist 
degradation, which is a desired requirement for a graft and lends to its durability. Although 
Dacron has been used for over a decade, its porous structure makes it susceptible to 
neointimal formation from infiltrating SMCs. Teflon grafts are limited in this same fashion 
and Teflon also elicits significant inflammation. However, Teflon does exhibit resistance 
to protein adsorption and thrombosis, both of which are necessary elements of a successful 
graft72. PU had greater success as a vascular graft.  PUs have both soft and hard domains 
that provide unique properties so it has strength while remaining flexible. Its tensile 
strength (20-90 MPa, depending on composition) is closer to the aorta, and it has 
viscoelastic properties so it is compatible with the native tissue. It also resists thrombosis. 
The main disadvantage to PU grafts is the degradation of the soft segments, but this can be 
addressed with polymer engineering to reinforce and stabilize the soft segments72,73. 
 While these grafts can replace the diseased aneurysmal aorta tissue, they still do 
not address the underlying causes of AAA formation and growth. The physiological and 
biochemical imbalance of matrix degradation and generation is still present, so the aorta 
remains susceptible to new AAA formation.  
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2.7 Strategies for regenerative repair of elastic matrix 
 In addition to reducing the proteolytic degradation of the elastic matrix, new elastic 
fibers must be produced to regenerate the elastic matrix to a healthy state in order to 
successfully treat AAAs. Tissue engineering can provide the necessary tools to meet this 
requirement. Broadly, tissue engineering seeks to generate functional, structural, and 
biological reproductions of native tissue to repair or completely replace diseased tissue72,73. 
Several strategies have been developed and implemented for use in AAA treatments, 
including the creation of polymer scaffolds, the use of stem cells for regeneration, and the 
delivery of pro-regenerative biological factors6. 
 
 
Figure 2.9 General approach for tissue engineering of blood vessels. Adapted from 
Pashneh-Tala et al 201673. 
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2.7.1 Scaffolds 
 A central characteristic of AAAs is a weakened and thinning vessel wall and 
biological or synthetic scaffolds can be used for strength and structural support while tissue 
regeneration occurs. Biological scaffolds include the decellularized tissues discussed in 
previous sections, while this section will focus on synthetic polymer based scaffolds. In 
general, a porous scaffold structure is created in the necessary size and shape parameters 
for the patient for use as a blood vessel73. The porous structure allows for the infiltration 
and population of cells, either while implanted in the body or from seeding in vitro. Pro-
regenerative and elastogenic growth factors can be incorporated into the scaffold as well 
to amplify the effects. The goal is for the patient’s cells to eventually take over the scaffold 
and produce their own ECM components. The scaffold helps organize and direct the 
orientation and organization of the cells and ECM. As the polymer scaffold naturally 
degrades, a stable, biologically active blood vessel will remain73. This can be achieved with 
acellular scaffolds that are implanted in the body as well. However, care must be taken 
when selecting polymers to ensure their degradation products are not cytotoxic and can be 
cleared naturally by the body. Additionally, polymers must be chosen that will not impede 
cell growth, migration, or function. Commonly used polymers include polyglycolic acid 
(PGA), poly-L-lactide (PLLA), poly-ε-caprolactone (PCL), and poly(lactide-co-glycolide) 
(PLGA). These can be used in combination with natural polymers such as collagen, fibrin, 
and chitosan72,73. The many readily available polymers allows for the customization and 
optimization of scaffold production. For instance, changes in porosity, degradation rates, 
and mechanical properties can create scaffolds with different properties and uses74. These 
tissue engineered scaffolds are still in development and there are some problems that need 
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to be addressed73. Cells must still be acquired and need to be stimulated to produce elastin 
in order to successfully recreate the elastic matrix. 
2.7.2 Stem cells for elastin regeneration 
 Cell therapy involves the use of cells as treatment for a disease or disorder. This 
strategy can be implemented in AAA treatment by delivery of elastin producing cells to 
the aneurysmal tissue, but there are challenges. Mature adult vascular SMCs have poor 
elastogenic capabilities, therefore they cannot restore the net loss of elastin that occurs in 
AAAs75. Elastin production during fetal development is mainly carried out by SMCs, but 
it is aided by stem cells and their SMC-like progenitors/derivatives. This leads to the 
strategy of utilizing stem cells that will produce their own elastin and also stimulate 
aneurysmal SMCs to produce elastic matrix to restore matrix homeostasis in the 
aneurysmal tissue76.  
 Stem cells for cell therapy can come from donors, but autologous stem cells are the 
ideal choice due to the lack of immune response. Multipotent mesenchymal stem cells 
(MSCs) can be harvested from bone marrow, peripheral blood, and adipose tissue. MSCs 
can be further differentiated into many cell types, but they have beneficial properties as 
MSCs. Studies have suggested that MSCs stimulate elastic matrix regeneration and 
increase the gene expression of elastin. Stem cell therapy has the potential to bring about 
the necessary elastogenesis needed to regenerate the aneurysmal tissue wall76.  There is 
strong evidence in literature, including from our own lab, that stem cell/stem cell 
derivatives generate paracrine secretions, factors contained within, which provide pro-
elastogenic and anti-proteolytic stimuli that can benefit aneurysm repair6,76,77. That said, 
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stem cell therapy demands significant attention to quality control and innovation in 
processing besides targeted delivery to the site of treatment. Capitalizing on knowledge of 
biological factors secreted by these cells that provide regenerative benefit could form the 
basis for stem-cell inspired, but cell free, delivery approaches (e.g. nanoparticles) to effect 
AAA tissue repair. 
2.7.3 Biological factors  
 Another strategy for elastin regeneration seeks to target and enhance specific 
individual steps of elastic fiber assembly. Each step is associated with and regulated by a 
certain cellular microenvironment consisting of several biological factors such as growth 
factors (TGF-β1, IGF-1) and other biomolecules, nucleotides, enzymes, and vitamins. 
Elastic fiber synthesis as a whole can be improved if the right steps are enhanced. 
Incorporation of these pro-elastogenic biomolecules in scaffolds could dramatically 
improve their function. Alternatively, exogenous delivery can stimulate elastogenesis. 
TGF-β1, for instance, has been shown to increase elastin synthesis, LOX expression, and 
TIMP expression while decreasing MMP expression6.  
2.8 Doxycycline 
 MMP inhibition is a frequent target in therapies for AAA treatment. MMPs are 
overexpressed in aneurysmal tissue, so their inhibition would lead to a reduction in the 
proteolysis of the elastic matrix. This is significant since presence of elastic fibers has been 
shown essential for the faithful neoassembly of new fibers78.  DOX is a well-studied 
tetracycline derivative that non-specifically inhibits a wide range of MMPs via direct co-
ordination with the catalytic site and through transcriptional inhibition of MMP mRNA. 
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DOX treatment has had some success in limiting and slowing AAA growth in rat and mice 
models8,79. 
2.8.1 Oral DOX therapy 
 DOX has been used as an oral therapy in clinical trials for AAA treatment, but the 
mechanisms through which it acts and its outcome are unclear. One study found that pre-
operative DOX therapy for 14 days resulted in reduced neutrophil content in the aortal 
wall, which is heavily involved in AAA development along with the expected reduction of 
MMP expression and activity80. Regardless, DOX’s ability to inhibit MMP-2 and MMP-9 
is highly beneficial and undisputed. However, the high doses (30-50 mg/kg/day, equivalent 
to ~50 µg/mL in AAA tissue) needed for oral therapy and the resulting systemic circulation 
cause body wide side effects (e.g. musculoskeletal pain, inflammation, tendonitis) and 
uncontrolled inhibition of MMPs in healthy tissue where it partakes in normal matrix 
remodeling necessary for tissue homeostasis. More importantly, these high oral doses 
further inhibit elastin regeneration and crosslinking9,79. High doses of DOX also inhibit 
SMC proliferation, which further reduces the capability of aneurysmal tissue to produce 
the necessary matrix components. 
2.8.2 Biphasic dose effects of DOX 
 Unlike its inhibition of MMPs at high systemic doses, and concurrent inhibition of 
new elastic matrix and crosslinking, at low µg/mL doses (< 10 µg/mL) DOX has been 
recently shown in our lab to inhibit MMPs while additionally stimulating elastogenesis. 
This showcases its biphasic dose effects9. This revelation is significant because these low 
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doses of DOX potentially address the chronic proteolytic degradation of the elastic matrix 
and the lack of elastogenesis, both of which are the primary drivers of AAA growth. 
2.8.3 DOX delivery from nanoparticles (NPs) 
 Modalities to ensure localized, targeted, sustained and steady low level DOX 
dosing are necessary to take advantage of the anti-proteolytic and pro-elastogenic 
properties of DOX at low µg/mL doses. Our lab has developed and shown the benefits of 
multifunctional NPs to achieve low dose delivery of DOX9. The NPs consist of a PLGA 
core encapsulating DOX and cationic amphiphile stabilizers on the surface. As the PLGA 
degrades, DOX is released in a controlled, predictable manner. The DOX loading and 
molecular weight of the PLGA allow for customizable release in the appropriate dose 
range. Using a polymer with a higher or lower molecular weight can decrease or increase 
DOX release, respectively6. Additionally, polyethylene glycerol (PEG) can be used to 
create a diblock copolymer that enhances stealth properties and circulation time in vivo of 
NPs81. This allows low doses of DOX to be released in treatment to take advantage of its 
pro-elastogenic and anti-proteolytc properties. The NP components also act synergistically 
with DOX to provide these same benefits. The cationic amphiphiles are capable of MMP 
inhibition and provide hydrophobic domains to facilitate binding of the tropoelastin 
hydrophobic domains. The positive charge imparted on the NPs enhances attraction to the 
negatively charged cell membranes to increase aortal uptake and also stimulates LOX 
activity9. Therefore, these DOX laden NPs have the potential to effectively reduce the 
chronic proteolysis and stimulate the regeneration of the elastic matrix in AAAs. Figure 
2.10 shows a schematic demonstrating these effects. 
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Figure 2.10 Schematic showing pro-elastin regenerative and anti-proteolytic effects of 
multifunctional DOX-NPs for AAA wall repair. Reprinted with permission from 
Sivaraman et al (2012)6. 
 
2.9 JNK  
The mechanism underlying the dual effects of DOX at low doses is not yet clarified. 
Recent studies have shown C-jun-N-terminal kinase (JNK), a stress activated protein 
kinase, to be upregulated in AAA tissue. Increased expression and phosphorylation of JNK 
has been shown to increase expression of MMPs and also to antagonize TGF-β1 
expression71,82,83. The effects of the resulting increase in MMPs has already been covered, 
but TGF-β1 has a positive influence on elastin production so its attenuation is 
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undesirable9,84. For example, we have shown previously that TGF-β1 (exogenous or 
delivered from NPs) stimulates elastogenesis by aneurysmal SMCs in culture, but with 
limited effects on MMP production/activity6. Losy et al have shown that overexpression of 
TGF-β1 by genetically manipulated SMCs introduced into the AAA wall correlates 
strongly to AAA wall growth stabilization, although elastin regeneration was not studied85. 
JNK inhibition with the drug SP600125 has been shown to increase ECM biosynthesis and 
decrease MMP activity and reduce AAA growth10,86, which is similar to the effects seen at 
low DOX doses. While this mechanism of DOX is yet to be configured, the low target 
specificity of SP600125, and its poor ability to inhibit the chronically overexpressed MMP-
210,86, reduces its potential efficacy for AAA treatment and merits investigation of DOX as 
an alternative drug to target JNK. Therefore, DOX may be able to enact its beneficial 
effects through JNK inhibition while avoiding the disadvantages experienced with 
SP600125 treatment. Our study therefore seeks to clarify this mechanism of action of DOX 
at low doses and investigate in aneurysmal SMC cultures if the anti-MMP and pro-
elastogenic effects of DOX is mediated by its inhibition of JNK, and if levels of JNK 
inhibition can be used as a metric to assess quality and quantity of induced elastic matrix 
repair. Furthermore, we also seek to investigate delivery of DOX, released at doses 
optimized based on the metric of significant JNK inhibition, from multifunctional NPs 
composed of a diblock copolymer of PLGA and PEG and its effectiveness in both 
stimulating elastic matrix neoassembly and inhibiting MMP mediated proteolysis in the 
aneursmyal SMC cultures, and if these result are synergistically improved by the cationic-
amphiphile-surface functionalized PEG-PLGA nanocarriers. 
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1 Isolation and culture of SMCs from elastase perfusion-induced rat AAAs 
All animal procedures were conducted with approval of the Institutional Animal 
Care and Use Committee (IACUC) at the Cleveland Clinic (ARC # 2016-0581). The Clinic 
animal facility is AAALAC-approved and has animal assurance (#A3145-01; Expires 
12/31/2017). Aneurysmal rat aortic SMCs (EaRASMCs) were isolated from multiple adult 
male Sprague-Dawley rats at 14-days post-AAA induction via elastase infusion, as 
described in an earlier study by our group5.  The aortae were cut open longitudinally and 
the intimal layer scraped off gently with a scalpel. The medial layer was then dissected 
from the underlying adventitial layer, chopped into ~0.5 mm long slices, and washed twice 
with warm sterile phosphate buffered saline (PBS). These were pooled and enzymatically 
digested in DMEM-F12 cell culture medium (Invitrogen, Carlsbad, CA) containing 125 
U/mg collagenase (Worthington Biochemicals, Lakewood, NJ) and 3 U/mg elastase 
(Worthington Biochemicals) for 30 min at 37 °C, centrifuged (400 g, 5 min), and cultured 
over 2 weeks in T-75 flasks. The cells were cultured in DMEM-F12 medium (Invitrogen) 
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supplemented with 10% v/v fetal bovine serum (FBS; PAA Laboratories, Etobicoke, 
Ontario) and 1% v/v PenStrep (Thermo Fisher, South Logan, UT). The primary 
EaRASMCs obtained from these tissue explants were propagated over 2 weeks, passaged 
when they attained confluence, and cells pooled from multiple rats were used in culture 
studies at passages 2-6. Healthy rat aortic SMCs (RASMCs) were similarly isolated from 
rats not induced with AAAs, and cultured identically to the EaRASMCs. 
3.2 Experimental design for cell culture studies 
A summary of the experimental design for our culture studies is presented in Table 
3.1a and b. A first experiment (experiment 1) sought to generate initial evidence that DOX 
attenuates JNK expression by cytokine-activated EaRASMCs and to ascertain the 
downstream effects of such inhibition on proteolytic activity and elastic matrix 
neoassembly in longer term cultures upon a) one time and b) repeated DOX dosing 
regimens, both under conditions of chronic cytokine-induced matrix injury to elucidate 
effects of DOX exposure. In this experiment, DOX was supplemented to EaRASMCs at a 
single dose (5 g/mL) which was selected in the dose range at which we previously showed 
DOX-releasing nanoparticles to have both pro-elastogenic and anti-MMP effects9. Dosing 
of DOX was performed in parallel with cytokine stimulation, and differential effects on the 
above listed outcomes, determined. RASMCs and EaRASMCs were both seeded in 6 well 
plates (A = 10 cm2; USA Scientific, Ocala, FL,) at 30,000 cells per well and cultured for 7 
days in DMEM F-12 media with 10% v/v FBS and 1% v/v PenStrep. Medium was changed 
on day 3 post-seeding. These 7-day cultures were analyzed using Western blots and ELISA 
for key signaling proteins such as JNK, active phosphorylated JNK (pJNK), TGF-1, and 
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the elastolytic MMP-2 and -9, and gel zymography for MMP enzyme activities, as will be 
detailed in subsequent sections. Briefly, on day 7 post-seeding, the cultures were serum 
starved for 3 h with DMEM F-12 medium with 1% v/v FBS and 1% v/v PenStrep before 
treatment for 30 min with 10 ng/mL each of the cytokines tumor necrosis factor- alpha 
(TNF-α; PeproTech, Rocky Hill, NJ) and interleukin- 1 beta (IL-1β; Bio Basic Inc, Ontario, 
Canada) with or without doxycycline hyclate (DOX) (Sigma Aldrich, St. Louis, MO), 
supplemented at 5 μg/mL. Cell culture supernatants were then immediately collected and 
analyzed using ELISA as will be described below.  RASMCs cultured with no cytokines 
or DOX were designated healthy cell controls.  EaRASMC cultures treated with cytokines 
but not DOX served as the treatment controls. 
Table 3.1a Design of culture experiments to assess effects of exogenous DOX (single 
dose) on JNK, MMP/TIMP, and TGF- expression in cytokine (TNF-α and IL-1β; 10 
ng/ml each)-injured EaRASMC layers.   
 
Separately, cell layers intended for biochemical analysis of elastic matrix 
deposition and crosslinking, and for imaging of such matrix were cultured for 21 days, as 
described in Table 3.1b. Briefly, at 7 days post-seeding, the EaRASMC cultures were 
incubated for 30 min with the cytokines, in parallel with, or without DOX (5 g/ml; 
treatment controls). These were then switched back to culture in DMEM F-12 medium 
containing 10% v/v FBS and 1% v/v Penstrep and cultured further. RASMCs were also 
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cultured for 21 days and evaluated as healthy cell controls. While one sub-group of DOX-
treated EaRASMC cultures received only a single DOX dose as described above, another 
sub-group received repeat DOX treatments (same dose) on days 8 and 14 post-seeding 
following replacement of spent medium. After the initial cytokine-induced injury event, 
the three EaRASMC cultures also received additional cytokine treatment on days 8 and 14 
post-seeding to simulate chronic cytokine exposure. The treated and control cell layers 
were all harvested at 21 days post-seeding for imaging and biochemical analysis. 
 
Table 3.1b Design of experiment to assess effects of DOX dosing regimen (single or repeat 
additions of DOX at 5 µg/mL) on elastic matrix neoassembly and proteolytic activity in 
cytokine (TNF-α and IL-1β; 10 ng/ml each)-injured EaRASMC cultures.  Outcomes were 
measured in harvested cell layers at 21 days post-seeding.   
 
3.3 Experimental design for DOX dosing cell culture studies 
After identifying the more effective DOX treatment regimen, a second set of studies 
(experiment 2) sought to investigate the effects of DOX dosing on anti-MMP and pro-
elastogenic properties of cytokine-activated EaRASMCs at 7 and 21 days post-seeding 
(Table 3.2a and 3.2b). In this experiment, the treatments described in section 3.2 were 
followed, but DOX was supplemented at 0.1, 1, 10, 20, and 50 μg/mL.  Based on 
experiment 1, DOX treatment was repeated and cytokines reapplied after medium changes 
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in the 21 day cultures. RASMCs and cytokine-treated EaRASMCs were also cultured as 
healthy cell and treatment controls respectively. All cell layers were harvested and/or 
analyzed at 7 or 21 days post-seeding and the medium was collected and pooled after 
treatments (7 day cultures) and medium changes (21 day cultures). 
Table 3.2a Design of experiment to assess DOX dose–dependent effects on JNK, 
MMP/TIMP, and TGF-1 expression in cytokine (TNF-α and IL-1β; 10 ng/ml each)-
injured EaRASMC cultures.   
 
Table 3.2b Design of experiment to assess DOX dose-dependent effects on elastic matrix 
neoassembly and proteolytic activity in cytokine (TNF-α and IL-1β; 10 ng/ml each)-injured 
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EaRASMC cultures.  Outcomes were measured in harvested cell layers at 21 days post-
seeding.  DOX dosing was repeated at weekly intervals following cytokine injury at 7 days 
post-seeding.   
 
3.4 Western blot for JNK, pJNK, MMP 2 and 9, TIMP-1, and LOX proteins 
In the experiments above, expression of JNK (isoforms 1, 2, and 3), pJNK, MMP-
2 and -9, tissue inhibitor of matrix metalloprotease (TIMP-1), and lysyl oxidase (LOX) in 
control and DOX-treated cultures were semi-quantitatively assessed using Western blots. 
After 7 days of culture and subsequent treatment, the contents of two adjacent wells from 
a 6 well plate were pooled and harvested with RIPA buffer (Thermo Scientific, Waltham, 
MA) containing 1% v/v HaltTM protease inhibitor (Thermo Scientific) and 1% v/v HaltTM 
phosphatase inhibitor (Thermo Scientific). A total of n = 3 replicate samples were thus 
analyzed in each group. Total protein content was measured using a bicinchoninic acid 
(BCA) assay kit (Thermo Scientific). Maximum volumes of protein sample (15.6 µL) were 
loaded under reduced conditions to lanes of a NuPAGE® Novex® 10% Bis-Tris or 4-12% 
Bis-Tris pre-cast polyacrylamide gels (Thermo Scientific). SeeBlue® pre-stained protein 
standard (Invitrogen) was also loaded in a well to form a protein ladder for determination 
of molecular weight. After electrophoresis in NuPAGE® MOPS or MES SDS Running 
Buffer (Thermo Scientific), the gels were transferred onto nitrocellulose membranes using 
the iBlot® Western Blotting System (Invitrogen) and then blocked for 1 h at room 
temperature with a 1:1 mixture of PBS and Odyssey Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE). They were immunolabeled for 16 h at 4 °C with one of the 
following antibodies - rabbit monoclonal antibody against JNK isoforms 1,2,3 (1:1000 v/v 
dilution; Abcam, Cambridge, MA), polyclonal rabbit IgG antibody against p-JNK (1 
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µg/mL dilution; R&D Systems, Minneapolis, MS),  or polyclonal rabbit antibodies against 
MMP 2 (1:500 v/v dilution; Abcam), MMP 9 (1:500 v/v dilution; Abcam), TIMP-1 (1:100 
v/v dilution; Santa Cruz Biotechnology, Dallas, TX), and LOX (2.5 µg/mL dilution; 
Abcam), and with a mouse monoclonal antibody against β-actin (1:1000 v/v dilution; 
Sigma-Aldrich), the loading control. Secondary antibody labeling was performed for 1 h 
at room temperature using IRDye® 680LT goat-anti-rabbit (1:15,000 dilution) and IRDye® 
800CW goat-anti-mouse (1:20,000 dilution) polyclonal antibodies (LI-COR Biosciences). 
A LI-COR Odyssey laser-based scanning system was used to image the protein bands. JNK 
band intensities were quantified with Image Studio software and normalized to the 
intensities of the β-actin bands, for the respective cultures. 
3.5 Gel zymography for MMP activity 
Enzyme activities of the elastolytic MMPs-2 and -9 were assessed via gel 
zymography. After 7 days of culture and subsequent treatment, the contents of 3 sets of 
adjacent wells from each 6-well culture plate were pooled and harvested with RIPA buffer 
(Thermo Scientific) containing 1% v/v HaltTM protease inhibitor (Thermo Scientific) to 
create n = 3 replicate samples/ treatment group for analysis. After BCA analysis, volumes 
of cell lysate equivalent to 5 μg of total protein were loaded into each lane of a 10% 
zymogen gel (Invitrogen), along with a SeeBlue® pre-stained protein standard (Invitrogen), 
and MMP-2 and MMP-9 protein standards (EMD Millipore, Billerica, MA). The gels were 
run for 2 h at 125 V and then washed in 2.5% v/v Triton-X-100 for 30 min to remove SDS. 
The gels were then incubated for 48 h at 37 °C in Novex® Zymogen Developing Buffer 
(Thermo Scientific) to activate the MMPs. Following incubation, the gels were washed 
with water 3× for 10 min and stained for 1 h with SimplyBlueTM SafeStain (Thermo 
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Scientific). Water was used to de-stain the gels until clear bands were visible. They were 
then scanned and Image J was used to quantify band intensities. 
3.6 ELISA for TGF-β1 expression 
TGF-β1 secreted into the cell culture medium, collected from 7 day cultures post-
treatment, was quantified using an enzyme-linked immunosorbent assay (ELISA) (Abcam) 
per manufacturer instructions.  
3.7 DNA assay 
DNA content of the 21 day cell layers was measured via a fluorometric assay of 
Labarca and Paigen to determine cell proliferation over the culture period87. The cell layers 
were harvested at 1 and 21 days of culture in Pi buffer, sonicated on ice, and assayed for 
DNA content. Cell density was calculated assuming 6 pg of DNA per cell.  
3.8 Fastin assay for elastin 
 Total elastin content in the 21 day cell cultures was quantified using a Fastin assay 
(Accurate Scientific and Chemical, Westbury, NY), as described in recent publications by 
our lab9,77. Cell layers from two wells each were pooled to create each sample and harvested 
in Pi Buffer and sonicated (n = 3 samples per culture group). To extract elastin, 500 μL of 
the cell suspensions were digested in 100 μL of 1.5M oxalic acid at 95 °C for 90 min, 
centrifuged at 14,000 g, and the supernatant containing the solubilized elastin was 
extracted. The remaining pellet was further digested with 400 μL of 0.25M oxalic acid at 
100°C for 1 h and centrifuged again at 14,000 g. The two supernatants were pooled and the 
elastin content was assessed using the Fastin assay. Total elastin amounts in each case was 
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measured and was also normalized to their respective DNA contents to provide a reliable 
basis for comparison between groups. 
3.9 Desmosine assay 
After 21 days of culture, RASMC and EaRASMC layers were harvested in PBS 
and pelleted by centrifugation. The cell pellets were hydrolyzed with 6 N HCl for 48 h, 
evaporated to dryness and reconstituted in 400 µL of water. The samples were then filtered 
through a 0.45 µm filter and desmosine levels were determined using a competitive ELISA 
assay88. Desmosine crosslinker amounts were normalized to the total protein content in the 
respective samples, which was measured via a ninhydrin assay89. 
3.10 Immunofluorescence (IF) labeling 
Elastic matrix deposition in cultures receiving different DOX doses and in controls 
was visualized using immunofluorescence.  21 day cell cultures were seeded in glass 
chamber slides (NuncTM Lab-TekTM II Chamber SlideTM System, Thermo Scientific) at 
15,000 cells/well. Cell layers were subjected to the stated treatments at 7 days of culture 
and further cultured until day 21 post-seeding when they were fixed in methanol (Fisher 
Scientific; 4 C,  30 min). The fixed cell layers were washed with PBS and blocked for 20 
min with PBS containing 5% v/v goat serum (ThermoFisher Scientific). They were 
immunolabeled with rabbit anti-rat polyclonal antibody against elastin (1:100 v/v dilution, 
EMD Millipore) for 1 h at room temperature. After washing the cell layer 2 times with 
PBS, the secondary antibody labeling step was performed using AlexaFluor 488 goat anti-
rabbit (1:1000 v/v dilution, Invitrogen) for 1 h at room temperature in the dark. Cell layers 
were mounted with Vectashield containing the nuclear stain 4',6-Diamidino-2-
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Phenylindole, Dihydrochloride (DAPI; Vector Laboratories, Burlingame, CA). EaRASMC 
layers treated with the secondary probe alone (no primary antibody) were imaged as IF 
controls.  The cell layers were imaged using Leica SP8 confocal microscope (Leica 
Microsystems Inc, Buffalo Grove, IL) and 3D reconstructions of Z-stack overlays (0.74 
µm intervals was performed using Volocity® (PerkinElmer, Waltham, MA). 
3.11 Transmission Electron Microscopy (TEM) 
TEM was performed to qualitatively assess elastic matrix ultrastructure and density 
in cultures receiving different DOX doses. To image the deposited elastic matrix, 21 day 
cell cultures as described in section 3.3 were seeded onto permanox chamber slides (A = 
4.2 cm2; Thermo Fisher; 15,000 cells per well). The cell layers were subjected to cytokine 
injury at 7 days of culture, with repeated cytokine addition and DOX dosing as described 
in section 3.3. TEM was performed only for cell layers receiving a DOX dose deemed to 
have most potent effects as deemed from western blots, gel zymography, and the Fastin 
assay. After 21 days of culture, the test and control cultures were rinsed with PBS (37 °C) 
and fixed (5 min, 37 °C, 4% w/v paraformaldehyde/ 2.5% w/v glutaraldehyde prepared in 
0.1 M sodium cacodylate buffer). Following this, the cell layers were incubated in the 
fixative overnight at 4 °C. The samples were post-fixed in 1% w/v osmium tetroxide (1 h), 
dehydrated in a graded ethanol series (50-100% v/v), embedded in Epon 812 resin, 
sectioned, placed on copper grids, stained with uranyl acetate and lead citrate, and imaged 
(using FEI Tecnai G2 Spirit) at multiple magnifications.   
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3.12 DOX-free NP formulation 
 NPs with varying concentrations of various cationic amphiphile stabilizers were 
developed and characterized to determine an optimal formulation to act as a nanocarrier to 
deliver DOX at the determined optimal target dose. 
Polyethylene glycol (PEG, 5,000 Da)-Poly (dl-lactic-co-glycolic acid) (PLGA, 
55,000 Da, 50:50 lactide: glycolide) methyl ether nanoparticles (NPs) (PEG-PLGA, Sigma 
Aldrich, St. Louis, MO) were fabricated via a single emulsion-solvent evaporation based 
technique. PEG-PLGA was dissolved in chloroform (Fisher Scientific, Fair Lawn, NJ) at a 
ratio of 25 mg of polymer to 1 mL of solvent. The water-in-oil emulsion was formed via 
sonication (Q500; QSonica LLC, Newtown, CT, 2 cycles of 30 s on ice at 20% amplitude) 
of an aqueous solution containing various cationic amphiphile stabilizers with the polymer 
solution. Various cationic stabilizers (Figure 3.1) namely Hexadecyltrimethylammonium 
bromide (CTAB, Sigma Aldrich, St. Louis, MO), Didodecyldimethylammonium bromide 
(DMAB, Sigma Aldrich, St. Louis, MO), Dodecyltrimethylammonium bromide (DTAB, 
Sigma Aldrich, St. Louis, MO), Octadecyltrimethylammonium bromide (OTAB, Sigma 
Aldrich, St. Louis, MO) at 0.25, 0.5, 1, and 1.5% w/v were evaluated to assess NP stability. 
This resulting emulsion was stirred overnight at room temperature, and then desiccated for 
1 h under vacuum, to remove any residual chloroform. The NPs formed were recovered by 
ultracentrifugation at 35,000 rpm (Beckman L-80, Beckman Instruments, Inc., Palo Alto, 
CA) for 30 min at 4 C. The NPs were washed twice with nanopure water to remove 
residual stabilizer (and unencapsulated DOX when applicable) and lyophilized for 48 h to 
obtain a dry powder.  
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Figure 3.1 Chemical structure of the cationic stabilizers used in the NP formulations. 
3.13 DOX-loaded NP formulation 
DOX-loaded PEG-PLGA NPs were fabricated as described above with minor 
modifications. PEG-PLGA NPs loaded with DOX were prepared via a double emulsion-
solvent evaporation technique. Briefly, the polymer was dissolved in chloroform at the 
same ratio. An aqueous DOX solution at three different loadings (2%, 5% and 10% w/w 
ratios of DOX: PEG-PLGA) was emulsified into the PEG-PLGA solution using a probe 
sonicator for 2 cycles of 10 s on ice, at an amplitude setting of 20%. The water-in-oil 
emulsion formed and was further emulsified into an aqueous solution of 1% w/v DMAB 
using the probe sonicator for 2 cycles at 30 s on ice at 20 % amplitude setting, to form the 
double emulsion. This second emulsion was stirred overnight at room temperature and NP 
fabrication was carried out as previously described.  
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3.14 Measuring DOX encapsulation efficiency  
The supernatants from the washing/ultracentrifugation steps were pooled for each 
individual NP formulation. The unencapsulated DOX was quantified via UV-
Spectrophotometry using the wavelength for DOX at λ = 270 nm (SpectraMax M2, 
Molecular Devices, Inc., Sunnyvale, CA). The total amount of DOX encapsulated in the 
NPs and the overall encapsulation efficiencies were determined by subtracting the total 
amount of unencapsulated DOX from the total weighed amounts of DOX added during NP 
formulation.   
3.15 Size and surface charge of DOX-loaded PEG-PLGA NPs 
Mean hydrodynamic diameters of the NPs were quantified using a dynamic light 
scattering (DLS) technique and the surface charge (mean zeta potentials) of these NPs due 
to the cationic surfactants were determined via a phase analysis light scattering technique 
using a commercial particle-sizing system (PSS/NICOMP 380/ZLS, Particle Sizing 
Systems, Santa Barbara, CA). For size determination, 5 L of NP solution was added to 
495 l of nanopure water. Each sample was run at 2 cycles for 5 min per cycle. For 
determination of surface charge, 500 l of the NP solution was combined with 2.5 mL of 
nanopure water. Samples were run for 2 cycles at 120 s per cycle.  
3.16 DOX release from NPs 
DOX release from NPs was carried out in phosphate buffer saline (PBS, pH 7.4; 
Sigma-Aldrich) at 37 ºC on a shaker at 250 rpm. Briefly, 1.5 mL polypropylene 
microcentrifuge tubes (n = 3 per formulation) were filled with 0.6 mL of NP suspensions 
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containing 0.2 and 0.5 mg/mL of NPs, respectively. Release studies were carried out for 
either 60 (2%, 5%, 10% w/w DOX to PLGA, 0.5 mg/mL) or 30 days (10% w/w DOX, 0.2 
mg/mL) in each case. At each analysis time point, the samples were centrifuged (14,000 
rpm, 30 min) in a microcentrifuge (Beckman Microfuge 16®, Beckman Coulter, Inc., 
Pasadena, CA), the supernatants withdrawn to quantify DOX content, and volume-
replenished with fresh PBS. UV-spectrophotometry was used to quantify the DOX release. 
DOX absorbance at λ = 270 nm was calibrated to its concentration using serial dilutions of 
a 0.2 mg/mL DOX solution. The DOX standards were incubated under the same conditions 
as the NP samples, to avoid any time and temperature-dependent degradation of DOX. 
3.17 Surface hydrophobicity of NPs  
PEG-PLGA NPs were formulated as described above and a Rose Bengal 
hydrophobicity assay was performed after the second washing step prior to lyophilization. 
A stock Rose Bengal (RB; Sigma Aldrich) solution was prepared by adding 20 mg of RB 
to 10 mL of nanopure water. This solution was then added to the NPs (10 µL/1 mL of NPs), 
covered to prevent light-generated degradation, and incubated on a shaker at 250 rpm for 
3 h. Following the incubation, the NPs were ultracentrifuged at 35,000 rpm at 4 ºC for 30 
min to collect the NP pellet from the supernatant. The supernatant was centrifuged again 
(Eppendorf Centrifuge, 5810R, 15 amps) at 4,000 rpm for 10 min to pellet any remaining 
NPs.  
The absorbance of the resulting supernatant was measured in a 96 well plate 
(Greiner Bio-one, Kremsmünster, Austria) via spectrophotometry (λ = 538 nm) and the 
absorbance was calibrated against serial dilutions of RB solution in nanopure water (20 
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µg/mL, 15 µg/mL, 10 µg/mL, 5 µg/mL, 2.5 µg/mL, and 0 µg/mL). Each surfactant (CTAB, 
DMAB, DTAB, and OTAB) was run individually and each surfactant concentration for 
each stabilizer (0.25%, 0.5%, 1%, and 1.5%) was run in triplicate. 
3.18 NP erosion profile 
NP erosion was qualitatively assessed over 20 days. NPs were weighed out and re-
suspended in PBS in 15 mL centrifuge tubes (USA Scientific) at concentrations of 0.2 
mg/mL and 0.5 mg/mL per batch. The NPs were then pelleted by centrifugation (4,000 rpm 
for 10 min) and incubated at 37 ºC (4, 6, 13, and 20 days respectively, n = 3 at each time 
point). At each time point, the supernatant was withdrawn and the samples were placed 
back, uncovered, in the incubator for 2 h to remove residual moisture. The masses were 
then recorded and the tubes were replenished with PBS per the appropriate concentration 
till the next assay time point.  
3.19 NP effects on cell viability 
The cytotoxicity of PEG-PLGA NPs was assessed using a LIVE/DEAD® viability 
assay (Invitrogen). Briefly, EaRASMCs were seeded at 30,000 cells/well in sterile, 6-well 
plates (Nalge Nunc International, Penfield, NY) and cultured over 7 days in DMEM-F12 
cell culture medium supplemented with 10% v/v FBS and 1% v/v PenStrep. The 10% w/w 
DOX loaded PEG-PLGA NPs were added to medium at a concentration of 0.2 mg/mL for 
24 h to offset the burst release and were then added to the EaRASMCs and incubated for 
24 h prior to assessing their viability. PEG-PLGA NPs containing no DOX were tested as 
active agent controls. The cells were stained with a Live/Dead® assay kit and viewed using 
an Olympus IX51 fluorescence microscope (Olympus America, Center Valley, PA). Cells 
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fluorescing red were identified as dead and those fluorescing green, as viable. Six different 
regions were assessed for each condition. 
3.20 Experimental design for cell culture studies to assess effects of NP treatment 
After determining an optimal DOX dose and NP formulation, the cell culture 
experiments previously described were repeated with the replacement of exogenous DOX 
treatments with treatments of DOX loaded NPs in experiment 3, outlined in Table 3.3a 
and b. Other than this, the treatment of the 7 day cultures was consistent. Briefly, 0.2 
mg/mL of DOX encapsulated NPs (DOX NPs) were reconstituted in DMEM F12 medium 
with 1% v/v FBS and 1% v/v PS two days prior to treatment to eliminate effects of the 
initial burst release of DOX. On day 7 post-seeding, following the 3 h serum starvation 
period, this medium was added to the cell layers in parallel with cytokine stimulation for 
30 min. The medium was collected and the cell layers were harvested for analysis. In 
addition to the previously described RASMC healthy cell controls and treatment controls, 
cytokine-activated EaRASMCs were treated with 0.2 mg/mL of NPs with no DOX (Blank 
NPs), prepared in the same manner described above, as a NP control culture. 
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Table 3.3a Design of culture experiment 3 to assess effects of DOX NPs on cytokine (TNF-
α and IL-1β; 10 ng/ml each)-injured EaRASMC layers (7 days).   
 
Separately, cell layers intended for biochemical analysis and imaging of elastic 
matrix deposition and crosslinking were cultured for a total of 21 days. Similar to the above 
experiment, at 7 days post-seeding following a 3 h serum starvation period, the EaRASMC 
cultures were incubated for 30 min with the cytokines, in parallel with, or without NPs 
(DOX NPs; Blank NPs; treatment controls). Healthy cell control and treatment control 
cultures were then switched back to culture in DMEM F-12 medium containing 10% v/v 
FBS and 1% v/v Penstrep. In the NP treated cultures, medium was collected and 
centrifuged to pellet any NPs not bound to the cell layer. The NP pellets were then re-
suspended in fresh DMEM F-12 medium containing 10% v/v FBS and 1% v/v Penstrep 
and saved for re-application on day 8 post-seeding. This procedure was followed again for 
medium changes on day 14 post-seeding, with normal medium changes for the healthy cell 
control and treatment control cultures. After the initial cytokine-induced injury event, the 
EaRASMC cultures also received additional cytokine treatment on days 8 and 14 post-
seeding to simulate chronic cytokine exposure. The treated and control cell layers were all 
harvested at 21 days post-seeding for imaging and biochemical analysis. The medium was 
also collected and pooled at every subsequent media change. 
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Table 3.3b Design of culture experiment 3 to assess effects of DOX NPs on elastic matrix 
neoassembly and proteolytic activity in cytokine (TNF-α and IL-1β; 10 ng/ml each)-injured 
EaRASMC cultures.  Outcomes were measured in harvested cell layers at 21 days post-
seeding.   
 
The conditions for performing Western blots, gel zymography, ELISA, DNA assay, 
Fastin assay, and the Desmosine assay described for experiment 1 and 2 were also applied 
to experiment 3. 
3.21 Amplex red peroxide assay for LOX enzyme activity 
 LOX activity in the cell culture medium collected from the periodic medium 
changes over the 21 day culture period was analyzed with an Amplex® Red Hydrogen 
Peroxide assay kit (ThermoFisher). Briefly, a working solution of 100 µM Amplex® Red 
and 0.2 U/mL horseradish peroxidase in PBS was added to an equal volume of cell layer 
supernatant to detect hydrogen peroxide produced by active LOX. 
3.22 Immunofluorescence (IF) detection of elastic matrix 
In the NP treatment studies, elastin in the extracellular matrix was visualized using 
immunofluorescence. Cell cultures (21 days) as described in Table 3.3b were seeded in 
glass chamber slides (NuncTM Lab-TekTM II Chamber SlideTM System, Thermo Scientific) 
at 15,000 cells/well. Cell layers were subjected to the stated treatments at 7 days of culture 
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and further cultured until day 21 post-seeding. On day 21 post-seeding, the cell layers were 
washed with PBS and then fixed in methanol (Fisher Scientific; 4 C, 30 min). The fixed 
cell layers were washed with PBS and blocked for 20 min with PBS containing 5% v/v 
goat serum (ThermoFisher Scientific) and were then immunolabeled with rabbit anti-rat 
polyclonal antibody against elastin (1:100 v/v dilution, EMD Millipore, Billerica, MA) for 
1 h at room temperature. After washing the cell layer 2× with PBS, the secondary antibody 
labeling step was performed using AlexaFluor 633 goat anti-rabbit (1:1000 v/v dilution, 
Invitrogen) for 1 h at room temperature in the dark. Cell layers were mounted with 
Vectashield containing the nuclear stain DAPI (Vector Laboratories). EaRASMC layers 
treated with the secondary probe alone (no primary antibody) were imaged as IF controls.  
The cell layers were imaged using a Leica SP8 confocal microscope and 3D reconstructions 
of Z-stack overlays (0.74 µm intervals) was performed using Volocity®, and the labeled 
elastic matrix was pseudo-colored to appear green. To determine fluorescence intensity, a 
corrected total fluorescence (CTF) protocol was used.  Briefly, the image field was selected 
using the rectangle tool in ImageJ to obtain an integrated density.  The integrated density 
was used to calculate the corrected total fluorescence for AF633 and DAPI.  The CTF is 
calculated by: (Integrated Density – (Mean Fluorescence of Background * Area of Selected 
Field)).  To normalize elastin content to nuclei, the average CTF of AF633 was divided by 
the average CTF of DAPI for each case.   
3.23 Transmission electron microscopy (TEM) of deposited elastic matrix  
TEM was first performed to qualitatively assess and compare the shape and size 
homogeneity of non-hydrated blank and DOX PEG-PLGA NPs. NPs were resuspended in 
milliQ water at a concentration of 5 mg/mL and 5 μL of this solution was transferred onto 
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a Formvar carbon-coated copper TEM grid (200 mesh size). The NP-containing grids were 
air dried for several hours and microscopy was performed. TEM images were obtained 
using a FEI Tecnai Biotwin (ThermoFisher Scientific) at 68 kV accelerating voltage. 
TEM was also performed to qualitatively assess elastic matrix ultrastructure and 
density in the NP treatment culture studies. To image the deposited elastic matrix, 21 day 
cell cultures were seeded onto permanox chamber slides (A = 4.2 cm2; Thermo Fisher; 
15,000 cells per well). The cell layers were subjected to the previously stated treatments 
and culture conditions, described in Table 3.3b. After 21 days of culture, the test and 
control cultures were washed with PBS (37 °C) and fixed (5 min, 37 °C, 4% w/v 
paraformaldehyde/ 2.5% w/v glutaraldehyde prepared in 0.1 M sodium cacodylate buffer). 
Following this, the cell layers were incubated in the fixative overnight at 4 °C. The samples 
were post-fixed in 1% w/v osmium tetroxide (1 h), dehydrated in a graded ethanol series 
(50-100% v/v), embedded in Epon 812 resin, sectioned, placed on copper grids, stained 
with uranyl acetate and lead citrate, and imaged at multiple magnifications.   
3.24 Statistical Analysis 
Where appropriate, data was analyzed using the Student t-test or one-way ANOVA. 
In all comparisons, statistical significance was defined at the standard 5% level. Microsoft 
Excel 2013 (Microsoft) and SigmaPlot 13.0 (Systat Software, Inc) were used in data 
analysis.  
61 
 
 
 
 
 
CHAPTER IV 
RESULTS 
 
4.1 Effects of DOX on expression of signaling proteins and MMPs/TIMP-1 
Western blots, gel zymography, and ELISA, as described in Chapter III, were 
performed to ascertain the effects of one time exogenous DOX exposure (5 μg/mL) on the 
signaling proteins JNK, pJNK, TGF-1, the elastolytic MMP-2 and -9, and TIMP-1 in 
experiment 1 (Table 3.1a).  
Western blot results for JNK (Figure 4.1A) show no significant difference in JNK 
1 expression in the treatment controls compared to the healthy cell controls. There was no 
significant difference in JNK 1 expression in the DOX-treated cultures compared to the 
controls. JNK 2 expression was significantly higher in the treatment controls compared to 
the healthy cell controls (p < 0.05). JNK 2 expression was significantly lower in the DOX-
treated cultures compared to the treatment controls (p < 0.01), but there was no significant 
difference compared to the healthy cell controls. Total JNK expression was significantly 
higher in the treatment controls compared to the healthy cell controls (p < 0.05). Total JNK 
expression was significantly lower in the DOX-treated cultures compared to the treatment 
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control (p < 0.05). There was no significant difference in total JNK expression in the DOX-
treated cultures compared to the healthy cell control cultures (Figure 4.1B). 
Figure 4.1 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of JNK on 
7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. A: Western blot for 
JNK isoforms; B: Western blot for total JNK. DOX-free EaRASMCs (treatment controls) 
and DOX-treated EaRASMCs are presented as normalized to RASMC healthy cell 
controls. Results shown are based on analysis of n = 3 cultures per group and represent 
mean ± SE. * and $ denote significance of differences versus RASMC healthy cell controls 
and treatment controls respectively, deemed for p < 0.05. 
 
Western blot results for pJNK (Figure 4.2A) show no significant difference in 
expression of pJNK (46 kDa) in the treatment controls compared to the healthy cell 
controls. There was no significant difference in pJNK (46 kDa) expression in the DOX-
treated cultures compared to the treatment controls. pJNK (54 kDa) expression was 
significantly higher in the treatment controls compared to the healthy cell controls (p = 
0.05). pJNK (54 kDa) expression was significantly lower in the DOX-treated cultures 
compared to the treatment controls and the healthy cell controls (p < 0.01). Total pJNK 
expression was significantly higher in the treatment controls compared to the healthy cell 
controls (p < 0.01).  Total pJNK expression (Figure 4.2B) was significantly lower in the 
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DOX treated cultures compared to the treatment controls (p < 0.01), but was not 
significantly different compared to the healthy cell controls.  
Figure 4.2 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of pJNK on 
7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. A: Western blot for 
pJNK isoforms; B: Western blot for total pJNK. DOX-free EaRASMCs (treatment 
controls) and DOX-treated EaRASMCs are presented as normalized to RASMC healthy 
cell controls. Results shown are based on analysis of n = 3 cultures per group and represent 
mean ± SE. * and $ denote significance of differences versus RASMC healthy cell controls 
and treatment controls respectively, deemed for p < 0.05. 
 
Western blot results for MMPs (Figure 4.3), show significantly higher expression 
of the activated (62-64 kDa) and zymogen (72 kDa) form of MMP-2 in treatment controls 
relative to healthy cell controls (p < 0.05). Active MMP-2 expression was significantly 
lower in DOX-treated cultures compared to the treatment controls (p < 0.05), but was still 
significantly higher compared to the healthy cell controls (p < 0.01). Inactive MMP-2 (72 
kDa) expression was significantly higher in the treatment controls compared to the healthy 
cell controls (p < 0.01). There was no significant difference in inactive MMP-2 expression 
in DOX-treated cultures compared to the treatment controls, but it was significantly higher 
compared to the healthy cell controls (p < 0.05). MMP-9 protein was not detected in any 
of the culture groups.  
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Figure 4.3 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of MMP-2 
on 7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. Western blot for 
MMP-2. DOX-free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are 
presented as normalized to RASMC healthy cell controls. Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. * and $ denote significance 
of differences versus RASMC healthy cell controls and treatment controls respectively, 
deemed for p < 0.05. 
 
Gel zymography sought to assess the enzymatic activity of MMPs-2 and-9 (Figure 
4.4). MMP-2 activity was significantly higher in the treatment controls compared to the 
healthy cell controls (p = 0.05). MMP-2 activity was significantly lower in DOX-treated 
cultures compared to the treatment controls (p = 0.001) but not different compared to the 
healthy cell controls.  MMP-9 enzyme activity was not detected in any of the culture 
groups. 
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Figure 4.4 Effects of exogenous DOX at a trial dose of 5 g/ml on MMP-2 enzymatic 
activity on 7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. Gel 
zymography analysis for MMP-2 enzyme activity. DOX-free EaRASMCs (treatment 
controls) and DOX-treated EaRASMCs are presented as normalized to RASMC healthy 
cell controls. Results shown are based on analysis of n = 3 cultures per group and represent 
mean ± SE. $ denotes significance of differences versus treatment controls, deemed for p 
< 0.05. 
 
Western blot results of TIMP-1 (Figure 4.5) show no significant differences in 
TIMP-1 expression in the treatment controls compared to the healthy cell controls. There 
was no significant difference in TIMP-1 expression in the DOX-treated cultures compared 
to the controls. 
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Figure 4.5 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of TIMP-1 
on 7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. Western blot for 
TIMP-1. DOX-free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are 
presented as normalized to RASMC healthy cell controls. Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE.  
 
ELISA results (Figure 4.6) show significantly lower TGF-1 expression in the 
treatment controls compared to the healthy cell controls (p < 0.05). TGF-1 expression 
was significantly higher in DOX-treated cultures compared to the treatment controls (p < 
0.05), but there was no significant difference compared to the healthy cell controls. 
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Figure 4.6 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of TGF-1 
on 7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. ELISA for TGF-
1. DOX-free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are 
presented as normalized to RASMC healthy cell controls. Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. * and $ denote significance 
of differences versus RASMC healthy cell controls and treatment controls respectively, 
deemed for p < 0.05. 
 
4.2 Effects of DOX dosing regimen on elastic matrix deposition and crosslinking 
 The effects of the differences in DOX treatment regimens (Table 3.1b) on elastic 
matrix deposition and crosslinking were also investigated in experiment 1. 
 DNA assay results (Figure 4.7) show significantly higher DNA content (i.e. cell 
proliferation) in the treatment controls compared to the healthy cell controls (p < 0.0001). 
DNA content was significantly lower in the repeated DOX-treated cultures compared to 
the treatment controls (p < 0.001), but was significantly higher compared to the healthy 
cell controls (p < 0.01). DNA content was significantly higher in the one-time DOX-treated 
cultures compared to the repeated DOX-treated cultures and the healthy cell controls (p < 
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0.01 and p < 0.0001, respectively), but there was no significant difference compared to the 
treatment controls. 
 
Figure 4.7 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on cell 
proliferation in 21 day cultures of cytokine-activated EaRASMCs. Outcomes in the DOX-
free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are presented as 
normalized to RASMC healthy cell controls (532 ng DNA/mL). Results shown are based 
on analysis of n = 3 cultures per group and represent mean ± SE. *, $, and # indicate 
significance of differences versus RASMC healthy cell controls, DOX-free treatment 
controls, and repeated DOX-treated cultures respectively, deemed for p < 0.05. 
 
 Fastin assay results normalized to cell count (Figure 4.8) show no significant 
difference in elastic matrix production per cell in the treatment controls compared to the 
healthy cell controls. Elastic matrix production per cell was significantly higher in the 
repeated DOX-treated cultures compared to the treatment controls and the healthy cell 
controls (p < 0.05). There was no significant difference in elastic matrix production per 
cell in the one-time DOX-treated cultures compared to the other culture groups. 
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Figure 4.8 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on elastic 
matrix deposition in 21 day cultures of cytokine-activated EaRASMCs. Outcomes in the 
DOX-free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are presented 
as normalized to RASMC healthy cell controls (95.7 ng elastin per ng DNA). Results 
shown are based on analysis of n = 3 cultures per group and represent mean ± SE. * and $ 
indicate significance of differences versus RASMC healthy cell controls and DOX-free 
treatment controls, respectively, deemed for p < 0.05. 
 
Western blot results for LOX (Figure 4.9) show no significant differences in LOX 
expression in the treatment controls compared to the healthy cell controls or the DOX 
treated cultures. To be noted, unlike the other analyses that were performed on 21 day 
cultures, that western bots for LOX were performed on 7 day EaRASMC cultures 
immediately following cytokine injury and DOX exposure. 
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Figure 4.9 Effects of exogenous DOX at a trial dose of 5 g/ml on expression of LOX on 
7-day cultures of EaRASMCs subject to 30 minutes of cytokine injury. Western blot for 
LOX. DOX-free EaRASMCs (treatment controls) and DOX-treated EaRASMCs are 
presented as normalized to RASMC healthy cell controls. Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. 
 
Desmosine ELISA results (Figure 4.10) show significantly lower desmosine 
crosslinker amounts in the treatment controls compared to the healthy cell controls (p < 
0.01).  There was no significant difference in desmosine amounts in the DOX-treated 
cultures compared to the treatment controls, but was significantly lower compared to the 
healthy cell controls (p < 0.05). There was no significant difference in desmosine amounts 
between the DOX-treated cultures. 
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Figure 4.10 Effects of DOX treatment regimen (one time or repeat doses; 5 g/ml) on 
desmosine crosslinking of elastic matrix in 21 day cultures of cytokine-activated 
EaRASMCs. Outcomes in the DOX-free EaRASMCs (treatment controls) and DOX-
treated EaRASMCs are presented as normalized to RASMC healthy cell controls. Results 
shown are based on analysis of n = 3 cultures per group and represent mean ± SE. * 
indicates significance of differences versus RASMC healthy cell controls, deemed for p < 
0.05. 
 
IF labeling results (Figure 4.11) show significantly higher amounts associated with 
the cell layers, which included both intracellular and extracellular tropoelastin (green) in 
repeat DOX-treated EaRASMC cultures relative to one-time DOX treated cultures. In both 
DOX-treated culture groups, fluorescence due to the elastic matrix was significantly higher 
than in the treatment controls. Elastic matrix deposition in healthy cell controls was similar 
to the treatment controls.  
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Figure 4.11 Immunofluorescence (IF) micrographs of the elastic matrix (green). DAPI-
stained nuclei appear blue. Elastic matrix deposition in repeat DOX-treated cultures (1) 
was significantly higher than in one time DOX-treated cultures (2), and in turn higher than 
in treatment controls (3). Elastin in the RASMC cultures was similar to the treatment 
controls (4). Also shown are IF controls that received no primary antibodies and exhibited 
no background when treated with the AF 488-conjugated secondary antibody (5). 
Extracellular elastic matrix deposits were clearly seen only in the DOX-treated culture 
groups (white arrows). Scale bars are 100 µm. 
 
4.3 Effects of DOX dose on signaling proteins and MMPs/TIMP-1 
In experiment 2 (Table 3.2a), we sought to ascertain the effects of DOX at doses 
of 0.1, 1, 10, 20, and 50 μg/mL on the expression of the signaling proteins JNK, pJNK, 
TGF-β1, and on the elastolytic MMP-2 and -9, and TIMP-1. DOX doses at 20 and 50 
μg/mL were found to significantly reduce cell proliferation and in the longer term, cause 
some cytotoxicity, and thus were not pursued further. 
Western blot results for JNK (Figure 4.12A) show no significant difference in JNK 
1 expression in the treatment controls compared to the healthy cell controls. There was no 
significant difference in JNK 1 expression in the DOX-treated cultures compared to the 
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treatment controls or healthy cell controls, and there was also no significant difference 
between DOX doses. JNK 2 expression was significantly higher in the treatment controls 
compared to the healthy cell controls (p < 0.001). JNK 2 expression was significantly lower 
in the DOX-treated cultures compared to the treatment controls (p < 0.001) and the healthy 
cell controls (p < 0.001 vs. 0.1 and 10 μg/mL DOX, p = 0.016 vs. 1 μg/mL DOX). Dose 
effects of DOX on JNK 2 expression were observed, with increased expression in 1 μg/mL 
DOX-treated cultures compared to 0.1 and 10 μg/mL DOX-treated cultures (p = 0.016 and 
p = 0.009, respectively). Total JNK expression (Figure 4.12B) was significantly higher in 
the treatment controls compared to the healthy cell controls (p < 0.001). Total JNK 
expression was significantly lower in the DOX-treated cultures compared to the treatment 
controls (p < 0.001). There was no significant difference in total JNK expression between 
the DOX-treated cultures and the healthy cell controls or between cultures treated with 
different DOX doses. 
 
Figure 4.12 Effects of exogenous DOX dose on expression of JNK in 7-day cultures of 
EaRASMCs subject to 30 minutes of cytokine injury. A: Western blot for JNK isoforms; 
B: Western blot for total JNK. Outcomes in the RASMC healthy cell controls and DOX-
treated EaRASMCs are presented as normalized to DOX-free EaRASMCs (treatment 
controls). Results shown are based on analysis of n = 3 cultures per group and represent 
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mean ± SE.*, $, %, and # represent significance of differences versus RASMC healthy cell 
controls,  DOX-free treatment control, 0.1 µg/mL DOX-treated cultures, and 1 µg/mL 
DOX-treated cultures, respectively, deemed for p < 0.05. 
 
Western blot results for pJNK (Figure 4.13) show significantly higher expression 
of pJNK (46 kDa) in the treatment controls compared to the healthy cell controls (p < 
0.001). pJNK (46 kDa) expression was significantly lower in DOX-treated cultures 
compared to the treatment controls (p = 0.001 vs. 0.1 and 1 μg/mL DOX and p < 0.001 vs. 
10 μg/mL DOX). There was no significant difference between the DOX-treated cultures 
and the healthy cell controls, or between the tested DOX doses. pJNK (54 kDa) protein 
was not detected in the blot. 
 
Figure 4.13 Effects of exogenous DOX dose on expression of p-(active) JNK in 7-day 
cultures of EaRASMCs subject to 30 minutes of cytokine injury. Western blot for pJNK. 
Outcomes in the RASMC healthy cell controls and DOX-treated EaRASMCs are presented 
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as normalized to DOX-free EaRASMCs (treatment controls). Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. $ represents significance of 
differences versus DOX-free treatment control, deemed for p < 0.05. 
 
Western blot results for MMPs (Figure 4.14) show significantly higher expression 
of active MMP-2 (62 kDa) (Figure 4.14A) in the treatment controls compared to the 
healthy cell controls (p < 0.001).  Active MMP-2 expression was significantly lower in the 
DOX-treated cultures compared to the treatment controls (p < 0.001). Active MMP-2 
expression was significantly higher in 1 μg/mL DOX-treated cultures compared to 0.1 and 
10 μg/mL DOX-treated cultures (p = 0.028 and p = 0.036, respectively) and was 
significantly higher in 1 μg/mL DOX-treated cultures compared to healthy cell controls (p 
= 0.013). Total MMP-2 expression (62-64 kDa), (Figure 4.14B) was also significantly 
higher in the treatment controls compared the healthy cell controls (p < 0.001). Total 
MMP-2 expression was significantly lower in DOX-treated cultures compared to the 
treatment controls (p < 0.001 vs. 0.1 and 10 μg/mL DOX and p = 0.002 vs. 1 μg/mL DOX). 
There was no significant difference in total MMP-2 expression between the 0.1 and 10 
μg/mL DOX-treated cultures and the healthy cell controls, but expression was significantly 
higher in the 1 μg/mL DOX-treated cultures compared to healthy cell controls (p = 0.014). 
Inactive MMP-2 (72 kDa) was not detected in these cultures. Similarly, MMP-9 protein 
was not expressed in any of the cultures. 
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Figure 4.14 Effects of exogenous DOX dose on expression of MMP-2 in 7-day cultures of 
EaRASMCs subject to 30 minutes of cytokine injury. A: Western blot for MMP-2 (62kDa); 
B: Western blot for total MMP-2. Outcomes in the RASMC healthy cell controls and DOX-
treated EaRASMCs are presented as normalized to DOX-free EaRASMCs (treatment 
controls). Results shown are based on analysis of n = 3 cultures per group and represent 
mean ± SE. *, $, %, and # represent significance of differences versus RASMC healthy 
cell controls,  DOX-free treatment control, 0.1 µg/mL DOX-treated cultures, and 1 µg/mL 
DOX-treated cultures, respectively, deemed for p < 0.05. 
 
Gel zymography results (Figure 4.15) show significantly higher MMP-2 activity 
in the treatment controls compared to the healthy cell controls (p = 0.008). MMP-2 activity 
was significantly lower in the DOX-treated cultures compared to the treatment controls (p 
< 0.001) and the healthy cell controls (p = 0.008 vs. 0.1 μg/mL DOX, p = 0.005 vs. 1 
μg/mL DOX, p = 0.011 vs. 10 μg/mL DOX). There was no significant difference between 
the DOX doses. MMP-9 enzyme activity was not detected in any cultures. 
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Figure 4.15 Effects of exogenous DOX dose on MMP-2 enzyme activity in 7-day cultures 
of EaRASMCs subject to 30 minutes of cytokine injury. Gel zymography analysis for 
MMP-2. Outcomes in the RASMC healthy cell controls and DOX-treated EaRASMCs are 
presented as normalized to DOX-free EaRASMCs (treatment controls). Results shown are 
based on analysis of n = 3 cultures per group and represent mean ± SE. * and $ represent 
significance of differences versus RASMC healthy cell controls and DOX-free treatment 
control, respectively, deemed for p < 0.05. 
 
Western blot results for TIMP-1 (Figure 4.16) show no significant difference in 
TIMP-1 expression in the treatment controls compared to the healthy cell controls. There 
was no significant difference in TIMP-1 expression in the DOX-treated cultures compared 
to the treatment controls. TIMP-1 expression was significantly higher in the 10 μg/mL 
DOX-treated cultures compared to the healthy cell controls (p < 0.05). There is no 
significant difference in TIMP-1 expression between the DOX doses. 
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Figure 4.16 Effects of exogenous DOX dose on expression of TIMP-1 in 7-day cultures 
of EaRASMCs subject to 30 minutes of cytokine injury. Western blot for TIMP-1. 
Outcomes in the RASMC healthy cell controls and DOX-treated EaRASMCs are presented 
as normalized to DOX-free EaRASMCs (treatment controls). Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. * represents significance of 
differences versus RASMC healthy cell controls, deemed for p < 0.05. 
 
ELISA results (Figure 4.17) show significantly lower TGF-β1 expression in the 
treatment controls compared to the healthy cell controls (p = 0.005). TGF-β1 expression 
was significantly higher in the 10 μg/mL DOX-treated cultures compared to the 0.1 μg/mL 
DOX-treated cultures and the treatment controls (p < 0.001 and p = 0.004, respectively), 
but there was no significant difference compared to the 1 μg/mL DOX-treated cultures and 
the healthy cell controls. TGF-β1 expression was significantly higher in the 1 μg/mL DOX-
treated cultures compared to the 0.1 μg/mL DOX-treated cultures (p < 0.001), but there 
was no significant difference compared to the treatment controls and healthy cell controls. 
TGF-β1 expression was significantly lower in the 0.1 μg/mL DOX-treated cultures 
compared to the treatment controls and healthy cell controls (p = 0.005 and p < 0.001, 
respectively).  
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Figure 4.17 Effects of exogenous DOX dose on expression of TGF-1 in 7-day cultures 
of EaRASMCs subject to 30 minutes of cytokine injury. ELISA for TGF-1. Outcomes in 
the RASMC healthy cell controls and DOX-treated EaRASMCs are presented as 
normalized to DOX-free EaRASMCs (treatment controls). Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. *, $, and % represent 
significance of differences versus RASMC healthy cell controls,  DOX-free treatment 
control, and 0.1 µg/mL DOX-treated cultures, respectively, deemed for p < 0.05. 
 
4.4 Effects of DOX dosing on cell proliferation and on elastic matrix deposition and 
crosslinking 
 DNA assay results (Figure 4.18) show significantly higher DNA content (cell 
proliferation) in the treatment controls compared to the healthy cell controls (p = 0.03). 
Cultures treated with 0.1 μg/mL DOX proliferated significantly more rapidly versus the 1 
and 10 μg/mL DOX-treated cultures (p = 0.013 and p < 0.001, respectively) and also the 
treatment controls and the healthy cell controls (p < 0.001). DNA content in the 1 μg/mL 
DOX-treated cultures was significantly greater compared to the 10 μg/mL DOX-treated 
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cultures and the healthy cell controls (p = 0.007 and p = 0.006, respectively), but there was 
no significant difference compared to the treatment controls. The 10 μg/mL DOX-treated 
cultures had significantly lower DNA content compared to the treatment controls (p = 
0.005), but was not different from the healthy cell controls. 
 
Figure 4.18 Effects of exogenous DOX dose on cell proliferation in 21 day cell cultures 
of cytokine-injured EaRASMCs. DOX was dosed to cells at weekly intervals following 
cytokine injury. Outcomes in the RASMC healthy cell controls and DOX-treated 
EaRASMCs are presented as normalized to DOX-free EaRASMCs (treatment controls) 
(1803 ng DNA/mL). Results shown are based on analysis of n = 3 cultures per group and 
represent mean ± SE. *, $, %, and # represent significance of differences versus RASMC 
healthy cell controls,  DOX-free treatment control, 0.1 µg/mL DOX-treated cultures, and 
1 µg/mL DOX-treated cultures, respectively, deemed for p < 0.05. 
 
Fastin assay results normalized to cell count (Figure 4.19) show no significant 
difference in elastic matrix production per cell in the treatment controls compared the 
healthy cell controls. Elastic matrix production was significantly higher in the 10 μg/mL 
DOX-treated cultures compared to the 0.1 and 1 μg/mL DOX-treated cultures (p < 0.001), 
and the treatment controls and the healthy cell controls (p < 0.001). Elastic matrix 
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production was significantly increased in the 1 μg/mL DOX-treated cultures compared to 
the 0.1 μg/mL DOX-treated cultures (p < 0.001), but there was no significant difference 
compared to the treatment controls and the healthy cell controls. Elastic matrix production 
was significantly lower in the 0.1 μg/mL DOX-treated cultures compared to both the 
treatment controls and the healthy cell controls (p = 0.008 and p = 0.003, respectively).  
 
Figure 4.19 Effects of exogenous DOX dose on elastic matrix deposition in 21 day cell 
cultures of cytokine-injured EaRASMCs. DOX was dosed to cells at weekly intervals 
following cytokine injury. Outcomes in the RASMC healthy cell controls and DOX-treated 
EaRASMCs are presented as normalized to DOX-free EaRASMCs (treatment controls) 
(85.2 ng elastin per ng DNA). Results shown are based on analysis of n = 3 cultures per 
group and represent mean ± SE. *, $, %, and # represent significance of differences versus 
RASMC healthy cell controls,  DOX-free treatment control, 0.1 µg/mL DOX-treated 
cultures, and 1 µg/mL DOX-treated cultures, respectively, deemed for p < 0.05. 
 
 Western blot results for LOX (Figure 4.20) show no significant difference in LOX 
expression in the treatment controls compared to the healthy cell controls. Significantly 
higher expression of LOX was noted in the DOX-treated cultures compared to the 
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treatment controls (p = 0.005 vs. 0.1 μg/mL DOX, p = 0.002 vs. 1 μg/mL DOX, p = 0.004 
vs. 10 μg/mL DOX) and the healthy cell controls (p = 0.004 vs. vs. 0.1 μg/mL DOX, p = 
0.003 vs. 1 and 10 μg/mL DOX). There was no significant difference between the DOX 
doses. 
 
Figure 4.20 Effects of exogenous DOX dose on expression of LOX in 7-day cultures of 
EaRASMCs subject to 30 minutes of cytokine injury. Western blot for LOX. Outcomes in 
the RASMC healthy cell controls and DOX-treated EaRASMCs are presented as 
normalized to DOX-free EaRASMCs (treatment controls). Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. * and $ represent significance 
of differences versus RASMC healthy cell controls and DOX-free treatment control, 
respectively, deemed for p < 0.05. 
 
Desmosine assay results (Figure 4.21) show no significant difference in desmosine 
amounts between the treatment controls and the healthy cell controls. Desmosine amounts 
in the 0.1 μg/mL DOX-treated cultures were not significantly different compared to the 
controls. Desmosine amounts in the 1 μg/mL and 10 μg/mL DOX-treated cultures were 
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significantly higher compared to the 0.1 μg/mL DOX-treated cultures (p < 0.01), the 
treatment controls (p < 0.01), and the healthy cell controls (p < 0.01). 
 
 
Figure 4.21 Effects of exogenous DOX dose on desmosine crosslinking of elastic matrix 
in 21 day cell cultures of cytokine-injured EaRASMCs. DOX was dosed to cells at weekly 
intervals following cytokine injury. Outcomes in the RASMC healthy cell controls and 
DOX-treated EaRASMCs are presented as normalized to DOX-free EaRASMCs 
(treatment controls). Results shown are based on analysis of n = 3 cultures per group and 
represent mean ± SE. *, $, and % represent significance of differences versus RASMC 
healthy cell controls,  DOX-free treatment control, and 0.1 µg/mL DOX-treated cultures, 
respectively, deemed for p < 0.05. 
 
IF labeling for elastic matrix results (Figure 4.22) show more elastic matrix (green) 
in the extracellular space, as denoted with white arrows, and tropoelastin within the cell, in 
the 10 μg/mL DOX-treated cultures (Figure 4.22A) compared to the 1 g/mL DOX-treated 
cultures (Figure 4.22B), and significantly more so than the 0.1 μg/mL DOX-treated 
cultures (Figure 4.22C) and the treatment controls (Figure 4.22D). 
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Figure 4.22 Immunofluorescence (IF) micrographs showing significantly increased elastic 
matrix (green) deposition in 10 µg/mL DOX-treated EaRASMC cultures (A) versus 1 
µg/mL DOX-treated (B) and 0.1 µg/mL DOX-treated EaRASMC cultures (C) and 
treatment controls (D). Also shown are IF controls that received no primary antibodies and 
exhibited no background when treated with the AF 488-conjugated secondary antibody 
(E). All cell layers were cultured for 21 days with DOX added weekly following cytokine 
injury at 7 days. While in all cases tropoelastin was detected within the cells, extracellular 
elastic matrix deposits were also seen in the 10 µg/mL DOX-treated (white arrows). Scale 
bars are 100 µm. CTF values represent average CTF and st. dev, n = 3. 
 
Transmission electron micrographs (Figure 4.23) show significantly more elastic 
matrix and forming fibers, as denoted with white arrows, in the 10 μg/mL DOX-treated 
cultures (Figure 4.23A) compared to 1 μg/mL and 0.1 μg/mL DOX-treated cultures 
(Figure 4.23B and 4.23C)  which were in turn noticeably greater than in the treatment 
controls (Figure 4.23 D). 
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Figure 4.23 Transmission electron micrographs show significantly higher density of 
forming elastic fibers (white arrows) in 10 µg/mL DOX-treated EaRASMC cultures (A) 
compared to the 1 µg/mL DOX-treated (B) and 0.1 µg/mL DOX-treated EaRASMC 
cultures (C). The treatment control cultures (D), contained very few elastin deposits and 
no fibers. All cell layers were cultured for 21 days with DOX added weekly following 
cytokine injury at 7 days. 
 
4.5 Effects of choice of surfactant on PEG-PLGA NP properties  
 A Rose Bengal assay was performed on NPs prepared with different cationic 
surfactants (0.25, 0.5, 1.0, and 1.5% and CTAB, DMAB, DTAB, and OTAB) to measure 
their hydrophobicity. Additionally, the hydrodynamic diameter and zeta potential was 
quantified for each NP preparation. Results (Figure 4.24a) suggest that DMAB imparted 
the highest hydrophobicity among the tested surfactants followed by DTAB, OTAB, and 
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CTAB. NP size (Figure 4.24b) for the most part was unaffected by choice of surfactant 
while the zeta potential (Figure 4.24c) was negative for DTAB alone, and positive in all 
other cases, with imparted surface charge with the latter formulations increasing in the 
order CTAB < DMAB < OTAB. 
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Figure 4.24 Effect of choice of cationic amphiphile surfactants and surfactant 
concentrations on hydrophobicity (A), hydrodynamic sizes (nm) (B), and surface zeta 
potential (mV) (C) of PEG-PLGA methyl ether NP formulations (n = 3 per group, mean ± 
st. dev). 
 
4.6 Formulation and characterization of DOX-loaded PEG-PLGA NPs 
The blank PEG-PLGA NPs exhibited a mean hydrodynamic diameter (or hydrated 
particle size) of 254.5 ± 36.8 nm and a ζ-potential of +24.2 ± 2.4 mV. Encapsulation at 2, 
5, 10% (w/w ratios to PEG-PLGA) did not significantly alter the size and surface charge 
of these PEG-PLGA NPs (Table 4.1). DOX encapsulation efficiencies ranged between 73-
87%. TEM (Figure 4.25) showed that non-hydrated PEG-PLGA NPs maintained their 
spherical morphology post-lyophilization with or without the encapsulation of DOX.  
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Table 4.1 Size and surface charge of PEG-PLGA NPs encapsulating DOX, formulated 
with DMAB as the emulsion stabilizer (n=3 replicate formulations; mean + st. dev). 
 
 
 
 
 
 
 
 
Figure 4.25 Transmission electron micrographs indicated similar morphology and size of 
0% and 10% w/w DOX-loaded PEG-PLGA-methyl ether NPs. 
 
4.7 DOX release from PEG-PLGA NPs in vitro 
The in vitro release profiles for DOX from PEG-PLGA NPs are shown at 0.5 
mg/mL for DOX loadings at 2, 5, and 10% w/w DOX to PEG-PLGA (60 days, Figure 
4.26A and B) and at 0.2 mg/mL (30 days, , Figure 4.27A and B). The DOX release curves 
obtained exhibit a biphasic release profile, which is characterized by an initial burst phase 
spanning the first couple days followed by a relative steady-state, near zero-order behavior 
from PEG-PLGA NPs. The cumulative release of loaded-DOX over 60 days was 79.4 + 
19.6%, 20.3 + 3.8%, and 7.7 + 3.2% for the 2, 5, and 10% DOX-loaded NPs at a 
concentration of 0.5 mg/mL. The cumulative release of DOX over 30 days was about 10% 
of the total DOX encapsulated for 10% w/w DOX-loaded PEG-PLGA NPs at 0.2 mg/mL, 
the NP concentration at which they were delivered to cells in culture studies below.  
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Figure 4.26 In vitro DOX release from PEG-PLGA methyl ether NPs loaded with 2, 5, 
and 10% w/w ratio of DOX to PEG-PLGA at a NP concentration of 0.5 mg/mL. Release 
was measured over 60 days and is shown as cumulative amounts (μg) released (A) and 
cumulative % of loaded DOX released (B) (n = 3 per group; mean ± st. dev). 
 
 
Figure 4.27 Plots showing time profile of in vitro DOX release from 10% w/w DOX-NPs 
at 0.2 mg/mL and 0.5 mg/mL concentrations, measured over 30 days. Plot in panel A 
indicates cumulative DOX amounts released (μg) and panel B indicates cumulative % of 
theoretically loaded DOX amounts.    
 
4.8 Erosion of PEG-PLGA NPs 
The erosion of 0% w/w DOX PEG-PLGA blank NPs was performed over 20 days 
at 0.2 and 0.5 mg/mL. The data (Figure 4.28A-C) shows a sharp decrease in mass of the 
NPs from day 0 to day 4 and a gradual decrease from day 4 to day 20. Over 20 days, 0% 
w/w DOX NPs at concentrations of both 0.2 mg/mL and 0.5 mg/mL exhibited ~44% loss 
in mass.   
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Figure 4.28 Panel A compares erosion profiles of 0% w/w DOX-NPs at concentrations of 
0.2 and 0.5 mg of NPs/mL, measured over 20 days. Burst release of DOX from 10% w/w 
DOX-NPs coincided with rapid initial erosion of the polymer nanocarriers, both at 0.2 mg 
of NPs/mL (Panel B) and 0.5 mg of NPs/mL (Panel C). Values shown indicate mean ± st. 
dev and were obtained by analysis of n=3 replicates per group. 
 
4.9 Assessing cytotoxicity of DOX-loaded PEG-PLGA NPs  
The design of our final PEG-PLGA NP formulations prepared with DMAB (1% 
w/v) is shown in Figure 4.29. At a concentration of 0.2 mg/mL, blank and 10% w/w DOX-
loaded PEG-PLGA NPs did not affect the viability of EaRASMCs as assessed by a LIVE-
DEAD assay. The absence of any dead (red) cells in the fluorescence images for both the 
blank and 10% w/w DOX NPs demonstrate that the PEG-PLGA NPs were not cytotoxic 
(Figure 4.30). This assay was not performed at an NP dose of 0.5 mg/mL as it was found 
to cause cell death 2-3 days post addition to cell cultures.  
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Figure 4.29 Schematic showing design of DOX-releasing PEG-PLGA methyl ether NPs. 
 
Figure 4.30 A LIVE/DEAD cytotoxicity assay indicated EaRASMCs exposed for 24 h to  
0% and 10% w/w DOX-loaded PEG-PLGA-methyl ether NPs (0.2 mg of NPs/mL) to be 
viable, Scale bar = 100 µm. 
 
4.10 Effects of DOX NPs on signaling protein and MMPs/TIMP-1 expression  
 Western blot results for JNK (Figure 4.31A) show no significant difference in JNK 
1 expression in the treatment controls compared to the healthy cell controls. There was no 
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significant difference in JNK 1 expression in the DOX NP-treated cultures and Blank NP-
treated cultures compared to the treatment controls or healthy cell controls, or between the 
NP-treated cultures. JNK 2 expression was significantly higher in the treatment controls 
compared to the healthy cell controls (p < 0.0001). JNK 2 expression was significantly 
lower in the DOX NP-treated cultures and Blank NP-treated cultures compared to the 
treatment controls (p = 0.002 and p = 0.0007, respectively), but significantly higher 
compared to the healthy cell controls (p = 0.031 and p = 0.012, respectively). There was 
no significant difference in JNK 2 expression between the NP-treated cultures. Total JNK 
expression (Figure 4.31B) was significantly higher in the treatment controls compared to 
the healthy cell controls (p < 0.0001). Total JNK expression was significantly lower in 
DOX NP-treated cultures and Blank NP-treated cultures compared to the treatment controls 
(p = 0.0007 and p = 0.005, respectively), but significantly higher than the healthy cell 
controls (p < 0.0001 and p = 0.006, respectively). There was no significant difference in 
total JNK expression between the NP-treated cultures. 
 
Figure 4.31 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on expression of JNK in 7 day EaRASMC cultures following 30 min of incubation 
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in parallel with cytokine injury. A: Western blot for JNK isoforms; B: Western blot for 
total JNK. Outcomes in healthy cell controls (NP free RASMCs) and NP-treated 
EaRASMCs are presented as normalized to DOX-free EaRASMCs (treatment controls). 
Results shown are based on analysis of n = 3 cultures per group and represent mean ± SE. 
* and $ denote significance of differences versus RASMC healthy cell controls and 
treatment controls respectively, deemed for p < 0.05. 
 
 Western blot results for pJNK (Figure 4.32) show significantly higher pJNK (54 
kDa) expression in the treatment controls compared to the healthy cell controls (p = 0.011).  
pJNK (54 kDa) expression was significantly higher in DOX NP-treated cultures and Blank 
NP-treated cultures compared to the healthy cell controls (p = 0.02, and p = 0.007, 
respectively). There was no significant difference in pJNK (54 kDa) expression in DOX 
NP-treated cultures and Blank NP-treated cultures compared the treatment controls, or 
between the NP-treated cultures. pJNK (46 kDa) expression was not detected in the 
cultures. 
 
Figure 4.32 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on expression of pJNK in 7 day EaRASMC cultures following 30 min of 
incubation in parallel with cytokine injury. Western blot for pJNK (54 kDa) isoforms. 
Outcomes in healthy cell controls (NP free RASMCs) and NP-treated EaRASMCs are 
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presented as normalized to DOX-free EaRASMCs (treatment controls). Results shown are 
based on analysis of n = 3 cultures per group and represent mean ± SE. * and $ denote 
significance of differences versus RASMC healthy cell controls and treatment controls 
respectively, deemed for p < 0.05. 
 
 Western blot results for MMPs (Figure 4.33A) show significantly higher 
expression of active MMP-2 (62 kDa) in the treatment controls compared to the healthy 
cell controls (p = 0.001). Active MMP-2 expression was significantly lower in the DOX 
NP-treated cultures and Blank NP-treated cultures compared to the treatment controls (p = 
0.0026 and p = 0.006, respectively). There was no significant difference in active MMP-2 
expression in the DOX NP-treated cultures and Blank NP-treated cultures compared to the 
healthy cell controls, or between the NP-treated cultures. Total active MMP-2 (62-64 kDa) 
(Figure 4.33B) expression was significantly higher in the treatment controls compared to 
the healthy cell controls (p = 0.002). Total MMP-2 expression was significantly lower in 
the DOX NP-treated cultures and Blank NP-treated cultures compared to the treatment 
control (p = 0.004 and p = 0.008, respectively) and was significantly higher compared to 
the healthy cell controls (p = 0.026 and p = 0.024, respectively). There was no significant 
difference in total MMP-2 expression between the NP-treated cultures. MMP-9 protein 
was not expressed in any of the cultures.  
95 
 
 
Figure 4.33 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on expression of MMPs in 7 day EaRASMC cultures following 30 min of 
incubation in parallel with cytokine injury. A: Western blot for MMP-2 (62 kDa); B: 
Western blot MMP-2 (62-64 kDa). Outcomes in healthy cell controls (NP free RASMCs) 
and NP-treated EaRASMCs are presented as normalized to DOX-free EaRASMCs 
(treatment controls). Results shown are based on analysis of n = 3 cultures per group and 
represent mean ± SE. * and $ denote significance of differences versus RASMC healthy 
cell controls and treatment controls respectively, deemed for p < 0.05. 
 
 Gel zymography results (Figure 4.34) show significantly higher MMP-2 activity 
in the treatment controls compared to the healthy cell controls (p = 0.0005). MMP-2 
activity was significantly lower in the DOX NP-treated cultures and Blank NP-treated 
cultures compared to the treatment controls (p = 0.015 and p = 0.007, respectively) and to 
the healthy cell controls (p = 0.03). There was no difference in MMP-2 activity between 
the NP-treated cultures. MMP-9 enzyme activity was not detected in any of the cultures. 
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Figure 4.34 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on MMP-2 enzymatic activity in 7 day EaRASMC cultures following 30 min of 
incubation in parallel with cytokine injury. Gel zymography analysis for MMP-2 enzyme 
activity. Outcomes in healthy cell controls (NP free RASMCs) and NP-treated EaRASMCs 
are presented as normalized to DOX-free EaRASMCs (treatment controls). Results shown 
are based on analysis of n = 3 cultures per group and represent mean ± SE. * and $ denote 
significance of differences versus RASMC healthy cell controls and treatment controls 
respectively, deemed for p < 0.05. 
 
 Western blot results for TIMP-1 (Figure 4.35) show significantly higher TIMP-1 
expression in the treatment controls compared to the healthy cell controls (p = 0.033). 
There was no significant difference in TIMP-1 expression in the DOX NP-treated cultures 
and Blank NP-treated cultures compared to the treatment controls or the healthy cell 
controls. There was no significant difference in TIMP-1 expression between the NP-treated 
cultures. 
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Figure 4.35 Effects of DOX-free (Blank) NPs and 10% w/w DOX-loaded NPs (0.2 
mg/mL) on expression of TIMP-1 in 7 day EaRASMC cultures following 30 min of 
incubation in parallel with cytokine injury. Western blot for TIMP-1. Outcomes in healthy 
cell controls (NP free RASMCs) and NP-treated EaRASMCs are presented as normalized 
to DOX-free EaRASMCs (treatment controls). Results shown are based on analysis of n = 
3 cultures per group and represent mean ± SE. $ denotes significance of differences versus 
treatment controls, deemed for p < 0.05. 
 
 ELISA results for TGF-β1 (Figure 4.36) show significantly lower TGF-β1 
expression in the treatment controls compared to the healthy cell controls (p = 0.02). TGF-
β1 expression was significantly higher in the DOX NP-treated cultures compared to the 
Blank NP-treated cultures, the treatment controls, and the healthy cell controls, and (p = 
0.02, p = 0.02, and p = 0.048, respectively). There was no significant difference in TGF-
β1 expression in the Blank NP-treated cultures compared to the treatment controls or the 
healthy cell controls. 
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Figure 4.36 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
expression of TGF-β1 in cytokine-activated EaRASMC cultures, as analyzed with ELISA. 
Untreated RASMC cultures were analyzed as healthy cell controls and NP untreated 
cytokine activated EaRASMCs as treatment controls. All values are shown normalized to 
the treatment controls. Results shown are based on analysis of n = 3 cultures per group and 
represent mean ± SE. *, $, and & denote significance of differences deemed for p < 0.05 
compared to healthy cell controls, treatment controls; and blank NP-treated cultures, 
respectively. 
 
4.11 Effects of DOX NPs on cell proliferation, elastic matrix deposition and 
crosslinking 
DNA assay results (Figure 4.37) show significantly higher DNA content (cell 
proliferation) in the treatment controls compared to the healthy cell controls (p < 0.0001). 
Cell proliferation was significantly lower in the DOX NP-treated cultures and Blank NP-
treated cultures compared to the treatment controls (p = 0.0004 and p = 0.003), but 
significantly higher compared to the healthy cell controls (p < 0.0001). There was no 
significant difference between the NP treated cultures. 
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Figure 4.37 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
cell proliferation in 21 day cell cultures of cytokine-activated EaRASMCs, as analyzed 
with a DNA assay. Also shown are NP-untreated RASMCs (healthy cell controls). All 
values have been shown normalized to outcomes in cytokine-activated, but NP-untreated 
EaRASMC cultures (treatment controls) (2017 ng DNA/mL).  Results shown are based on 
analysis of n = 3 cultures per group and represent mean ± SE. *, $ denote significance of 
differences deemed for p < 0.05 compared to RASMC healthy cell controls and treatment 
control respectively. 
 
Fastin assay results (Figure 4.38) show no significant difference in elastic matrix 
production in the treatment controls compared to the healthy cell controls. Elastic matrix 
production was significantly higher in the DOX NP-treated cultures compared to the Blank 
NP-treated cultures, the treatment controls, and the healthy cell controls (p = 0.04, p = 
0.002, and p = 0.0004, respectively). Elastic matrix production was significantly higher in 
the Blank NP-treated cultures compared to the treatment controls and the healthy cell 
controls (p = 0.002 and p = 0.0006, respectively). 
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Figure 4.38 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
elastic matrix deposition (normalized to cell count) in 21 day cell cultures of cytokine-
activated EaRASMCs, as analyzed with a Fastin assay. Also shown are NP-untreated 
RASMCs (healthy cell controls). All values have been shown normalized to outcomes in 
cytokine-activated, but NP-untreated EaRASMC cultures (treatment controls) (137.7 ng 
elastin per ng DNA). Results shown are based on analysis of n = 3 cultures per group and 
represent mean ± SE. *, $, and & denote significance of differences deemed for p < 0.05 
compared to RASMC healthy cell controls, treatment control and blank NP-treated 
cultures respectively. 
 
Western blot results for LOX (Figure 4.39) show no significant differences 
between any of the culture groups. As seen in (Figure 4.40), there was significantly lower 
LOX activity in the treatment controls compared to the healthy cell controls (p < 0.0001). 
LOX activity was significantly higher in the DOX NP-treated cultures compared to the 
treatment controls and the healthy cell controls (p = 0.005 and p < 0.0001). LOX activity 
was significantly lower in the Blank NP-treated cultures compared to the healthy cell 
controls (p = 0.02). There was no significant difference in LOX activity between the NP-
treated cultures. 
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Figure 4.39 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
LOX expression in 7 day cell cultures of cytokine-activated EaRASMCs, as analyzed with 
a Western blot. Also shown are NP-untreated RASMCs (healthy cell controls). All values 
have been shown normalized to outcomes in cytokine-activated, but NP-untreated 
EaRASMC cultures (treatment controls). Results shown are based on analysis of n = 3 
cultures per group and represent mean ± SE.   
 
 
Figure 4.40 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
LOX enzyme activity in 21 day cell cultures of cytokine-activated EaRASMCs, as 
analyzed with an Amplex® Red Hydrogen Peroxide assay. Also shown are NP-untreated 
RASMCs (healthy cell controls). All values have been shown normalized to outcomes in 
cytokine-activated, but NP-untreated EaRASMC cultures (treatment controls). Results 
shown are based on analysis of n = 3 cultures per group and represent mean ± SE. *, $ 
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denote significance of differences deemed for p < 0.05 compared to RASMC healthy cell 
controls and treatment control respectively. 
 
Desmosine assay results (Figure 4.41) show significantly lower desmosine 
crosslinker amounts in the treatment controls compared to the healthy cell controls (p = 
0.0025). Desmosine amounts were significantly lower in the DOX NP-treated cultures 
compared to the Blank NP-treated cultures, the treatment controls, and the healthy cell 
controls (p = 0.013, p = 0.048, and p = 0.001 respectively). There was no significant 
difference in desmosine content in the Blank NP-treated cultures compared to the treatment 
controls, but desmosine content was significantly lower in the Blank NP-treated cultures 
compared to the healthy cell controls (p = 0.003). 
 
Figure 4.41 Effects of DOX-free (Blank) NPs and 10% w/w DOX-NPs (0.2 mg/mL) on 
desmosine crosslinker amounts in 21 day cell cultures of cytokine-activated EaRASMCs, 
as analyzed with ELISA Also shown are NP-untreated RASMCs (healthy cell controls). 
All values have been shown normalized to outcomes in cytokine-activated, but NP-
untreated EaRASMC cultures (treatment controls). Results shown are based on analysis of 
n = 3 cultures per group and represent mean ± SE. *, $, and & denote significance of 
differences deemed for p < 0.05 compared to RASMC healthy cell controls, treatment 
control and blank NP-treated cultures respectively. 
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IF labeling for elastic matrix results (Figure 4.42) show more elastic matrix (green) 
in the extracellular space, as denoted with white arrows, and tropoelastin within the cell, in 
the DOX NP-treated cultures (Figure 4.42A) compared to the Blank NP-treated cultures 
(Figure 4.42B) and the treatment controls (Figure 4.42C) and greater expression of 
tropoelastin within cells in the Blank NP-treated cultures compared to the treatment 
controls.  
 
Figure 4.42 Immunofluorescence (IF) micrographs showing significantly increased elastic 
matrix (green) deposition  in 10% w/w DOX-NP treated (A) and blank NP treated (B) 
EaRASMC cultures (21 days) versus treatment controls (C). Also shown are IF controls 
that received no primary antibodies and exhibited no background when treated with the AF 
633-conjugated secondary antibody (pseudo-colored green). While in all cases tropoelastin 
was detected within the cells, extracellular elastic matrix deposits were also seen in the NP 
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treated cultures (white arrows). Arrows indicate extracellular matrix in the NP treated 
cultures. Scale bars are 100 µm. CTF values represent average CTF and st. dev, n = 3. 
 
Transmission electron micrographs (Figure 4.43) show significantly more elastic 
matrix and forming fibers in the DOX NP-treated (Figure 4.43A) and Blank NP-treated 
(Figure 4.43B) cultures versus the treatment controls (Figure 4.43C) 
 
Figure 4.43 Transmission electron micrographs show significantly higher density of 
forming elastic fibers (white arrows) in DOX-NP (A) and blank NP treated (B) EaRASMC 
cultures compared to the treatment controls (C), which contained very few elastin deposits 
and no fibers. All cell layers were cultured for 21 days. 
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CHAPTER V 
DISCUSSION 
 
Small AAAs (< 5 cm in diameter) are currently detected early with proactive image 
based screening of high risk individuals (e.g., elderly Caucasian male smokers). However, 
once diagnosed, these AAAs are not actively treated until they attain a critical size (> 5.5 
cm maximal diameter), beyond which the risk of rupture exceeds surgical risk. 
Endovascular or open surgery are performed only at this stage. Management of smaller 
AAAs is limited to passive imaging based growth monitoring and there are strong 
opportunities for active treatment to arrest or reverse AAA growth during this years long 
growth phase. AAAs are characterized by the chronic proteolytic breakdown of the ECM 
by upregulated MMPs and the inherent inability of mature SMCs to generate new elastic 
fibers, resulting in a net loss of elastic matrix and further weakening of the aortal wall7,75,90. 
Our long term goal is to develop an active and minimally invasive treatment approach to 
reduce the chronic proteolytic breakdown of elastic fibers in the ECM and simultaneously 
stimulate elastic fiber assembly (elastogenesis) towards restoring matrix homeostasis in the 
AAA wall to slow, arrest or even reverse AAA growth. In clinical trials, DOX, an MMP 
inhibitor, is prophylactically administered (~50 mg/kg/day equivalent to ~30 g/cm3 in 
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AAA wall) to AAA patients in an attempt to inhibit MMPs in the AAA wall to slow the 
growth of AAA. However, systemic DOX dosing causes body wide inhibition of MMPs, 
which are involved in matrix turnover in healthy tissues. Additionally, regeneration of the 
elastic matrix does not occur because the high doses of this DOX therapy inhibit the 
deposition of new, crosslinked elastic matrix by SMCs8,71,91,92. This problem was addressed 
in a prior study, where we showed for the first time that at a much lower dose (< 10 g/ml), 
DOX retains its anti-proteolytic effects, while actually stimulating elastogenesis9. 
 The dual effects of low dose DOX resemble similar outcomes observed with the 
drug SP600125, which is known to inhibit the stress-activated protein kinase, c-jun-N-
terminal kinase (JNK)86. JNK is upregulated in AAA tissue and its inhibition with 
SP600125 in mice has been shown to increase elastin mRNA and matrix crosslinking while 
also reducing MMP activity and apoptosis, which are linked to AAA regression10. 
However, we are motivated to investigate the use of DOX because SP600125 inadequately 
inhibits MMP-2, a proteinase that plays a central role in AAA etiology, and has poor target 
specificity93. While DOX is known to directly inactivate MMPs by engaging their active 
site and possibly by fragmentation of the protein91, in this study, we investigated if DOX 
can also act by inhibiting the JNK pathway. We also sought to determine if JNK attenuation 
can be used as a metric to gauge effectiveness of a therapeutic in decreasing MMP-
mediated proteolysis and increasing elastic matrix synthesis, crosslinking, and fiber 
formation. We tested these effects in cytokine-activated cultures of aneurysmal rat aortic 
SMCs isolated from a rat elastase-injury model that simulates human AAAs94–96. These 
SMCs have been extensively characterized in our prior work and maintain their diseased 
phenotype in culture and are responsive to elastogenic stimulation75. The cultures were 
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treated with the cytokines TNF-α and IL-1β because they are overexpressed in AAA tissue 
and are central to AAA pathophysiology97. An initial test dose of 5 µg/mL was used to 
assess the differences in one time DOX treatment versus repeated DOX treatment, based 
on our earlier published outcomes showing DOX released from nanocarriers in this 
approximate dose to have anti-MMP and pro-elastogenic effects9.  
Our study suggests that at this initial low dose, DOX attenuates total JNK protein 
expression to levels comparable to expression in the healthy RASMCs primarily by 
inhibiting the JNK 2 isoform. More importantly, expression of the active JNK isoform (p-
JNK) was reduced. Anti-proteolytic effects of JNK inhibition were observed with a 
significant reduction of active MMP-2 expression and enzymatic activity. The decrease in 
active MMP-2 is important due to its role in the enzymatic degradation of the elastic matrix 
in AAA tissue. MMP-9, another key protease in AAA pathology, was not detected but this 
was not unexpected based on our prior work in which we showed minimal protein 
expression in cultured SMCs9,12. At our initial test dose, TIMP-1 protein expression was 
not effected by DOX treatment, which is beneficial because it can continue to counter 
MMPs, specifically elastolytic MMPs-2 and -9, to further reduce net proteolytic activity. 
Pro-elastogenic effects of JNK inhibition were also observed. Upon DOX inhibition of 
JNK 2, TGF-β1 expression levels rose significantly, which has been shown to increase 
elastin production75 and that its overexpression slows AAA growth in mice98. This is also 
consistent with literature that shows JNK antagonizes TGF-β1 expression11,83,99. In this 
single dose study, we sought to investigate differences in new elastic matrix production 
and deposition upon one time DOX treatment and repeated DOX treatment and exposure. 
From our results, we conclude that repeated DOX treatments alone significantly stimulate 
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elastic matrix deposition relative to treatment controls and healthy cell controls. Although 
LOX production appeared above that in RASMC healthy cell controls, the increase was 
not statistically significant. This accounts for the desmosine crosslink levels in DOX-
treated cultures to remain lower than that in the RASMC cultures. Importantly, IF showed 
density of elastic matrix in repeat DOX-treated cultures to be significantly higher than the 
one-time DOX-treated cultures, recapitulating the outcomes of the Fastin Assay. Based on 
these findings, subsequent DOX dose studies involved repeat DOX dosing events. 
While we initially tested DOX doses as high as 50 g/ml (data not shown), we 
showed significant inhibition in cell proliferation at doses of 10 g/ml and higher, with 
cytotoxicity observed at 20 and 50 g/ml doses, which is consistent with findings by other 
groups100,101. Similar to the initial single dose test, DOX dosing primarily inhibited the JNK 
2 isoform while attenuating total JNK protein expression and active p-JNK expression. 
While all three doses (0.1, 1, and 10 µg/mL DOX) reduced JNK expression to levels 
significantly below both the treatment and healthy cell controls, there was only a mild 
negative correlation (r = -.38) (Table 5.1) between DOX dose and JNK-2 expression (i.e. 
JNK 2 decreases with DOX dose increase) across this dose range. This is a result of the 
poor correlation between DOX dose and JNK 2 in the 0.1 – 10 µg/mL dose range especially 
considering the dramatic drop in JNK 2 levels between 0 and 0.1 µg/mL doses. While this 
merits a study to explore DOX effects in this tighter dose range, the results also indicate 
that DOX is a potent inhibitor of JNK 2. Consistent with the significant inhibition of JNK 
2, we also observed significant decreases in active MMP-2 expression levels down to levels 
measured in healthy RASMCs. The strong positive correlation between JNK 2 and MMP-
2 expression (r = 0.88, Table 5.1) indicates JNK 2 is a very strong regulator of MMP-2. 
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Comparing these findings to the weaker correlation between MMP-2 and DOX (r = -0.57) 
suggests that DOX inhibition of MMP-2 also occurs through other JNK-independent 
mechanisms with weaker DOX dose dependency; this is highly relevant in the context of 
earlier findings showing DOX to engage and inactivate the active site of the MMP and also 
cause its fragmentation91. At the 10 µg/mL DOX dose, TIMP-1 expression was 
significantly higher than in the control cultures, which as discussed previously, is beneficial 
since TIMP-1 counters MMP-2 to reduce net proteolytic activity in the cultures. Our data 
clearly shows that higher TGF-β1 levels correspond to reduced expression of JNK 2, as 
seen in comparisons between the treatment and healthy cell control cultures, and with the 
0.1 µg/mL DOX-treated aneurysmal SMC cultures. This is consistent with the previously 
published findings showing antagonism between JNK and TGF-β111,99. However, overall 
TGF-β1 showed very mild negative correlation to JNK 2 in the 0-10 µg/mL dose range (r 
= 0.15, Table 5.1), likely due to lack of DOX dose effects on JNK 2 in this dose range. 
Also, in light of the strong positive correlation between DOX dose and TGF-β1 expression 
(r = 0.79, Table 5.1) it might be inferred that DOX critically regulates TGF-β1 by 
mechanisms independent of JNK inhibition as well. 
 
Table 5.1 Correlation study results comparing DOX dose, JNK 2 protein expression 
levels, TGF-β1 protein expression levels, MMP-2 protein expression levels, elastic 
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matrix production, LOX protein expression levels, and desmosine crosslinker amounts. 
Values correspond to correlation coefficient (r value). 
 
The increase in TGF-β1 has vital implications to elastic matrix neoassembly in light 
of our previously published data showing exogenous TGF-β1 to stimulate elastogenesis 
and crosslinking of elastic matrix75. Also, work by Losy et al. showed TGF-β1 
overexpression by engineered SMCs seeded in the AAA wall to reduce MMP expression, 
enhance TIMP expression, and augment LOX synthesis, which were in turn linked to 
slowed AAA growth in mouse models85. 
As expected, in this study, elastic matrix production showed strong positive 
correlation to both DOX dose and TGF-β1 expression (r = 0.94 and 0.93, respectively, 
Table 5.1). However, elastic matrix production only mildly correlated negatively to JNK 
2 levels (r = -0.17, Table 5.1). Based on previous literature, we expected these increases 
in TGF-β1 expression and elastic matrix production upon JNK 2 inhibition86,102, but 
expected a stronger correlation with JNK 2. Our results suggest that there may be other 
signaling pathways, besides inhibition of JNK 2 that may be activated by DOX dosing to 
affect TGF-β1 expression and elastic matrix production. Interestingly, JNK 2 expression 
showed strong negative correlation (r = -0.995, Table 5.1) to LOX protein synthesis and a 
milder, positive correlation to DOX dose. Consistent with these trends in lysyl oxidase 
expression, desmosine crosslinker amounts in the cytokine-treated aneurysmal SMC 
cultures also showed strong, negative correlation (r = -0.59) to JNK 2 levels and a strong 
positive correlation (r = 0.58) to DOX dose. Our results indicate that at a dose of 0.1 µg/mL, 
DOX significantly stimulates proliferation of aneurysmal SMCs. While this can augment 
total elastic matrix production, rapid proliferation of the aneurysmal SMCs is not a 
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preferred outcome since AAAs are frequently associated with atherosclerosis, where 
plaque growth can be exacerbated by SMC proliferation. 
Our results suggest that while JNK inhibition by DOX plays an important role in 
augmenting anti-proteolytic activity and pro-elastin crosslinking, DOX may also act 
through other pathways to stimulate elastogenesis. Based on the collective assessments of 
the results, we infer that DOX causes significant inhibition of JNK 2 in the 0.1-10 µg/mL 
range to cause significant downstream anti-MMP effects and increases in LOX-mediated 
crosslinking of the elastic matrix. DOX also augments TGF-β1, in part via inhibition of 
JNK 2, but also by other mechanisms we have not presently identified to likely induce 
downstream increases in both elastic matrix synthesis and elastin crosslinking. 
Collectively, the pro-elastogenic and anti-proteolytic effects upon DOX treatment appear 
to benefit deposition of crosslinked elastic matrix, as indicated by IF and TEM. Our study 
outcomes suggest that a DOX dose of 1-10 µg/mL may be most beneficial (within the 
tested dose range) to achieve JNK-mediated anti-MMP and elastin neoassembly 
augmenting effects with minimal impact on cell proliferation, since a 0.1 µg/mL DOX dose 
induced hyper-proliferation of the aneurysmal SMCs and a 10 µg/mL dose slightly 
inhibited cell proliferation. AAA-tissue localized, and sustained low level DOX release 
within this defined dose range using NP vehicles would be a useful modality to provide 
pro-elastogenic and anti-MMP benefits while avoiding systemic DOX biodistribution and 
effects. Elastic fiber formation is also dependent on spatio-temporal coordination of a large 
number of other assembly proteins, besides elastin and LOX, which could potentially be 
augmented by JNK decreases and TGF-β1 increases. These merit investigation in follow 
up work. 
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To reduce DOX dosing to avail of its regenerative benefits, provide targeted and 
sustained action in the AAA wall and minimize systemic MMP inhibition, we have 
previously developed novel, multifunctional DOX-NPs9. These biodegradable polylactic-
co-glycolic acid (PLGA) NPs were designed to provide predictable, sustained & steady-
state low level DOX release locally in AAA tissue following single-event intra-aortal 
infusion. The NPs were surface-functionalized with cationic amphiphiles (DMAB) to 
provide pro-elastogenic and anti-MMP stimuli, independent of the released DOX9. These 
were attributed to the a) cationic groups and b) di-chain hydrophobic acyl groups presented 
by the pendant cationic amphiphiles on the NP surface. While the cationic moieties 
electrostatically attract LOX, which is anionic at physiologic pH, to enhance its local 
crosslinking activity103,104, they have also been shown to interact with anionic amino acids 
in the active site of the MMPs105, resulting in altered configuration of this site to render it 
unrecognizable to the complementary peptide sequences present in matrix proteins (e.g. 
elastin and collagen).  Differently, the hydrocarbon chains of the amphiphiles, through their 
binding to hydrophobic domains on elastin substrates has been suggested to change the 
molecular conformation of the latter to expose lysine residues for more ready crosslinking 
by LOX104. As we have previously published9, it is also possible that the long dodecyl 
chains of the DMAB sterically hinder the active site of the MMP leading to its inactivation. 
Due to these beneficial features, we have retained these design aspects in our current NP 
design.  
Different however, from our previous NP design we now use a PEG-PLGA 
copolymer instead of PLGA. PEG is known to provide stealth properties to NPs81,106, 
enhancing their circulation time and also limiting surface adsorption of plasma proteins 
113 
 
that could trigger their opsonization by macrophages in the AAA wall preventing their 
targeted effects on the aneurysmal SMCs. Since PEG is hydrophilic, we expected use of 
the copolymer to decrease surface charge and hydrophobicity of our NP formulations 
relative to what we previously achieved with DMAB modified PLGA NPs and for this 
reason, also tested other NP formulations prepared with DMAB homologues. While this 
was indeed the case, our NPs continued formulation using DMAB as a surfactant continued 
to maintain a) a significant positive charge (~20 mV), necessary to facilitate their uptake 
into the AAA wall107, electrostatically interact with SMCs which exhibit a net negative 
charge (resting membrane potential of -55 mV)108, and provide anti-proteolytic and pro-
elastin crosslinking effects, and b) a hydrophobic surface that would allow the NPs to bind 
to the exposed elastin core of elastic fibers in need of repair within the AAA wall for 
localized reparative activity. Kagan et al. also showed that hydrophobic binding of such 
amphiphiles to elastin changes its molecular conformation, leading to exposure of its lysine 
residues for crosslinking by LOX, outcomes that we will discuss separately104. However, 
the limitations of our hydrophobicity characterization utilizing Rose Bengal (RB) dye 
should be noted. It is possible that all of the surfactant does not stay attached to our NP 
throughout the formulation, therefore RB bound to these free surfactant molecules could 
be detected in the tested supernatant and could cause an artificially low result. NP size was 
not significantly altered by our choice of surfactant, with most NPs in the 200-300 nm size 
range we previously showed to exclude them to the extracellular space where matrix 
assembly occurs9. Therefore, our selection of DMAB as the surfactant of choice was based 
on a) DMAB generating NPs exhibiting the greatest hydrophobicity, a likely effect of their 
presenting two, not one hydrocarbon chains, and b) elimination of OTAB, which generates 
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surface charges (~+45 mV) high enough to potentially compromise viability of our cells9, 
and DTAB, since it consistently generated NPs exhibiting a negative rather than positive 
surface charge, an outcome likely influenced by the use of a diblock PEG-PLGA 
copolymer since we have previously generated PLGA NPs with a positive surface charge 
with the use of a DTAB surfactant9.  We hypothesize that the PEG chains mask the 
presence of the cationic moiety presented by the DTAB on the NP surface, preventing their 
detection.  
The DOX release profile from our NP formulations was consistent with what we 
reported previously with PLGA-based DOX-NPs 9 and also by others109,110. The burst 
release of DOX from PLGA based polymers during the first few hours, which coincides 
with and is due to rapid initial bulk erosion of the encapsulating polymer NP can be 
concerning in the context of inciting cytotoxic effects, and can also diminish prospects for 
sustained release of the drug from the NP over extended periods. Indeed, the DOX burst 
phase of our 2% w/w DOX-NP formulations resulted in release of ~20% of encapsulated 
DOX, though the generated DOX concentration itself was within our desired dose range, 
and the duration of the burst release was short.  However, with NPs containing higher DOX 
loadings, the burst release of DOX is not a concern. In our release curves, we also see that 
DOX release from the 5 and 10% w/w DOX-NPs is lower than that observed for 2% w/w 
DOX-loaded NPs. This could be attributed to more dense packing of the DOX within the 
polymer matrix at the higher loadings resulting in impeded infiltration of water, and 
subsequent out-diffusion of solubilized DOX. For this reason, unlike DOX release from 
the 2% w/w DOX-NPs, release from the 5% and 10% w/w DOX-NPs appears to be at 
steady state beyond the burst phase.  In addition, with the latter formulations, less than 10% 
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of the loaded DOX was cumulatively released at the 50 day time point, suggesting 
prospects to significantly extend DOX release beyond this period. Based on their ability to 
release DOX at near steady state within our desired dose range, we selected the 10% w/w 
DOX-NPs to pursue further for our culture experiments to gauge their effects on matrix 
production by EaRASMCs. An NP dose of 0.2 mg/mL, which maintained complete 
viability of EaRASMC cultures at the stated cell densities, was adopted for these culture 
studies.  
As did exogenous DOX, our DOX NPs also significantly inhibited JNK 2 and 
MMP-2, although no decreases in pJNK were noted and TIMP-1 increases were not 
significant. While as expected based on our prior published findings9, the blank NPs also 
significantly inhibited MMP-2 protein synthesis and enzyme activity, their significant 
inhibition of JNK 2 is noteworthy, and is likely due to JNK suppression by quaternary 
ammonium groups (presented by the DMAB) a finding first reported by Mendis et al111. 
Another observation was that the outcomes with the DOX NPs were deemed not 
statistically different from outcomes with the blank NPs. This could be attributed to our 
generated steady state DOX concentrations being at the lower end (2.5 g/mL) of our 
useful DOX dose range (1-10 g/mL).  However, TGF-1 expression by the EaRASMCs 
was impressively increased in the presence of DOX NPs but not blank NPs, and to levels 
significantly higher than even in healthy cell controls, suggesting substantial augmentation 
of elastic matrix neoassembly in these cultures. Indeed elastic matrix production was 
significantly higher in these cultures and blank NP-treated cultures than in treatment and 
healthy cell controls as indicated by biochemical analysis and IF and TEM imaging.  
However, our results also indicate little or no effect of the blank NPs and separately, the 
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DOX, on LOX protein synthesis, enzyme activity and desmosine crosslinking, which is 
contrary to expectations. While the lack of augmentation by blank NPs may be due to the 
effect of PEG chains in masking or steric hindering of functional groups presented by the 
DMAB on the NP surface, the mild effect of DOX could again be attributed to the low 
steady state doses generated with the 10% w/w DOX NP formulations. The results suggest 
a need to increase steady state DOX dosing from our NPs within our useful dose range, 
which can be accomplished by use of a co-polymer based on a lower molecular weight 
PLGA. Future studies must also investigate if use of PEG of lower molecular weight might 
mitigate the hypothesized steric hindrance or masking of DMAB on the NP surface. We 
believe these measures would serve to augment the pro-matrix regenerative effects 
attributed to our polymer nanocarriers and separately, the released DOX. 
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
 
In this work, we have shown that the dual, pro-elastogenic and anti-MMP effects 
of DOX are at least in part mediated by its inhibition of JNK 2, which triggers increases in 
TGF-1 to result in downstream attenuation of elastolytic MMP-2 and increases in elastic 
matrix deposition and lysyl oxidase-mediated crosslinking in aneurysmal SMC cultures. A 
schematic is provided in Figure 6.1. We have identified a useful DOX dose range wherein 
these effects are more pronounced. Our results suggest that JNK inhibition is a useful 
metric to assess pro-elastic matrix regenerative effects of DOX. We have also confirmed  
that we can achieve sustained and near steady-state DOX release within our useful dose 
range, from DMAB-functionalized PEG-PLGA NPs, and elicit pro-matrix regenerative 
effects mostly consistent with the effects of exogenous DOX. While our results provide 
evidence supporting the combinatorial regenerative benefits provided by DOX and 
cationic-functionalized NPs, the NP formulations must be further optimized (PEG and 
PLGA molecular weights) to mitigate possible masking of DMAB moieties on the NP 
surface and also to enhance steady state release levels of DOX within our identified dose 
range.   
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Figure 6.1 DOX-NP mechanisms of matrix regenerative repair for restoring ECM 
homeostasis in the aneurysmal aortic wall. The pro-elastogenic & anti-proteolytic 
properties (3) of our NPs will augment regenerative effects of released DOX by direct 
MMP inhibition (2) and by effects occurring downstream of inhibiting JNK (1) 
 
As noted in our dose study results, the correlation between DOX dose and JNK 
inhibition is very strong between 0 and 0.1 µg/mL, but the correlation coefficient weakens 
from 0.1 to 10 µg/mL due to the potency of DOX as a JNK inhibitor. Therefore, a more in 
depth dose study with additional doses between 0 and 0.1 µg/mL DOX should be 
performed to further elucidate this relationship and its downstream effects on MMP 
inhibition and new elastic matrix production. Additionally, the relationship between DOX 
and TGF-β1, independent of JNK, should be further explored. 
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As described in Chapter II, AAAs are also characterized by an increase in collagen 
content in the vessel wall (Figure 2.6), which leads to an increase in stiffness that can 
negatively affect blood flow dynamics. We have preliminary results suggesting that JNK 
overexpression leads to an increase in collagen production by aneurysmal SMCs. It is 
known that DOX has anti-fibrosis properties112. It is also known that TGF-1 increases, 
which we have shown to result downstream of JNK inhibition, but can also occur through 
other pathways, incite some degree of collagen production/fibrosis113. However, JNK is 
important for gene expression and protein synthesis of connective tissue growth factor 
(CTGF), which is essential for fibroblast activation and collagen synthesis114. Hence, DOX 
inhibition of JNK can certainly attenuate fibrosis to in turn reduce aortal tissue stiffening. 
Therefore, future work should be aimed at elucidating the effects of JNK inhibition on 
collagen production and how it can help maintain the balance between elastin and collagen 
content in the ECM of the regenerating vessel wall. Additional JNK inhibitory methods, 
such as AAA wall-localized JNK2 gene silencing with siRNA delivered from NPs can also 
be explored in a similar vein, which can be much more efficient. 
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